1	
2	
3	
4	Radiologist observations of chest X-rays (CXR) predict sputum smear microscopy status in TB
5	Portals, a real-world database of tuberculosis (TB) cases
6	
7	Gabriel Rosenfeld ^{1*} , Andrei Gabrielian ¹ , Alyssa Meyer ² , Alex Rosenthal ³
8	
9	
10 11 12 13	¹ Bioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
14 15 16 17	² Software Engineering Branch, Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
18 19 20	³ Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
21	* Corresponding author
22	E-mail: gabriel.rosenfeld@nih.gov

23 Abstract

24 The Tuberculosis (TB) Portals is an international program of 14 countries connecting clinical, 25 genomic, and radiologist specialists to develop an openly available repository of deidentified TB 26 cases with multi-modal data such as case clinical characteristics, pathogen genomics, and 27 radiomics. This real-world data resource contains over 4000 TB cases, principally drug resistant 28 cases, with over 4000 chest X-rays (CXR) images. The scope of curated data offers a case-29 focused perspective into the drivers of disease incorporating the chronological context of the 30 presented CXR data. Here, we analyze a cohort consisting of new TB cases to understand the 31 relationship between baseline sputum microscopy status and nearby Chest X rays images. The 32 Timika score, a lung biomarker of disease severity, was derived for each CXR using available 33 radiologist observations. The Timika score along with the radiologist observations were 34 compared for predictive performance of baseline sputum microscopy status. Baseline sputum 35 microscopy status is a useful marker of pre-treatment disease severity and infectiousness. The 36 modeling results support that both the radiologist observations as well as Timika score are 37 predictive of smear status and that Timika score performs similarly to the top 5 radiologist 38 features by feature selection. Moreover, inferential statistical analysis identifies the factors 39 having the greatest association with sputum smear positivity such as presence of radiologist 40 observations in both lungs, presence of cavity, presence of nodule, and Timika score itself. The 41 results are consistent with prior reports showing Timika Score utility for predicting baseline 42 sputum smear and disease status. We report testing of Timika Score on the largest, openly 43 available real-world dataset of TB cases that can serve as a reference to explore extant and new 44 TB disease severity scores bridging radiological, microbiological, and clinical data. To illustrate, 45 we visualize Timika score from images in our database with other cases characteristics

46 demonstrating that this score captures lung biomarker status consistent with known clinical risk47 factors.

48 Introduction

49 Tuberculosis (TB) remains a major global pandemic with approximately 10 million new 50 cases and 1.5 million deaths each year (1, 2). With the emergence of the SARS-Cov2 global 51 pandemic in 2020, it is estimated that the TB pandemic may have worsened due to additional 52 strains and challenges encountered via healthcare systems around the world (3, 4). Concurrent to 53 those unfortunate events, drug resistant TB continues to be a persistent threat with up to $\sim 20\%$ of 54 TB isolates around the world estimated to be resistant to a major drug. Transmission of drug 55 resistant TB is an emerging phenomenon closely monitored by health authorities worldwide (5). 56 Drug resistant TB cases (DR-TB) are associated with poorer outcomes and more expensive cost 57 of care when compared to drug sensitive TB. DR-TB has a lower treatment success of 58 approximately 55% globally and Multi- or Extensively DR-TB care can cost up to 25 times that 59 of TB cases that are drug sensitive (6, 7). Therefore, real-world databases focusing on these DR 60 cases that span multi-domain case information are essential to identify novel relationships and 61 aspects of drug resistance to enable translational medicine to timely and efficiently address drug resistance. 62

To eradicate TB, clinicians need rapid diagnostics of disease along with efficient means of monitoring treatment response and completeness at discharge. Sputum smear microscopy has been a primary method for diagnosis of pulmonary tuberculosis in low and middle income countries (LMIC) since it is a relatively simple, rapid, and less costly approach that can identify the most infectious patients and be applied in a variety of socio-economic status areas. Nonetheless, this approach shows deficiencies in certain demographic groups such as extra-

69 pulmonary TB, pediatric TB, and TB patients simultaneously infected with HIV (8). Moreover, 70 the requirement for repeated sputum sampling can present obstacles to the application of the 71 approach as patients may not return for results, are lost to follow up, or have difficulty producing 72 usable sputum samples. Despite these challenges, it is still widely used throughout LMIC for 73 disease monitoring and response to therapy (9) as well as having demonstrated some ability to 74 predict treatment response albeit requiring additional clinical factors (10). Since this 75 microbiological information is sometimes unavailable or inclusive, it is important to identify 76 other modalities that may assist with diagnosis or monitoring of treatment response, and one 77 such approach is imaging of the lungs via Chest X-rays (CXRs). 78 CXR imaging is often collected during TB disease management to understand treatment 79 response and disease status. Unlike computed tomography (CT) imaging that may not always be 80 available due to the cost of associated infrastructure (11), CXRs are the primary means of 81 assessing lung status in LMIC due to their relatively lower costs (12). As such, they are more 82 widely available to clinicians for assessing lung status during TB disease management and used 83 as a decision-making clinical information point compared to CTs. Radiologist assessment of 84 CXRs have been the gold standard reference upon which CXRs have been interpreted for clinical 85 decision making historically. These observations provide an important lung biomarker that can 86 inform patient risk, disease severity, and response to treatment over the course of a TB case. For 87 example, Heo et al. tracked radiological lesions from CXRs over the course of TB treatment in a 88 prospective cohort analysis showing that presence of cavity or fibrotic lesion associated with 89 poor radiological response (13). Another example is the development of CXR-derived Timika 90 Score that has been associated with baseline sputum smear microscopy status and disease 91 severity in TB cases (14, 15).

The National Institute of Allergy and Infectious Diseases (NIAID) Office of Cyber 92 93 Infrastructure and Computational Biology leads the transnational partnership of participating 94 sites covering 14 countries with heavy DR TB burden. This partnership created the TB Portals 95 to facilitate TB data sharing and science with a goal towards a better understanding of the real-96 world aspects of especially problematic DR TB. The TB Portals resource consists of a repository 97 of TB case data including multiple domains such as case clinical characteristics, pathogen 98 genomics, and radiomics that can support the biomedical research community's research efforts 99 towards TB. As of April 2021, the TB Portals database includes over 4000 TB cases, mostly 100 drug resistant cases, with over 4000 CXRs. Many of these cases also have radiologist 101 annotations for their CXRs to assess lung biomarker status in relation to the clinical and 102 microbiological characteristics of the case. While other resources have large numbers of chest 103 X-ray images, TB Portals provides a TB case-centered repository encapsulating the 104 chronological context associated with the CXR such as drug resistance status, regimens 105 administered so far, the genome of the pathogen, and sputum microscopy status. External 106 collaborators can apply for access to publicly shared data through an online data use agreement 107 (DUA) and then download this data to facilitate reproducibility and open science. 108 In this study, we utilize the radiologist observations for CXR images in the TB Portals 109 repository to derive Timika Score (15), a useful numerical lung biomarker, to assess its utility for 110 predicting sputum smear microscopy status. We compare Timika Score performance with other 111 features we derived from the radiologist-reported observations to determine if the additional 112 features could improve upon Timika's previously reported performance. We select a cohort of 113 cases with a case definition of new containing sputum smear microscopy results from specimens

taken prior to start of treatment, as well as CXRs with radiologist observations within two weeks

115	of the specimen date. We perform inferential statistical analysis of risk of positive sputum
116	microscopy from presence of various features derived from radiologist observations. We also
117	examine Timika Score in relation to other aspects of the case such as demographics, case
118	definition, and outcome. For instance, we utilize a strength of this resource in having a larger
119	number of mono drug resistant (Mono DR), poly drug resistant (Poly DR), Multi-drug resistant
120	(MDR) and Extensively drug resistant (XDR) according to WHO guidelines (16).
121	We report results consistent with prior publications regarding the utility of the Timika
122	score for predicting baseline sputum status. Importantly, we show that Timika Score offers
123	similar predictive performance compared to the top 5 features we derive from radiologist
124	observations. These results suggest that Timika Score is well-optimized for determining pre-
125	treatment disease infectiousness and severity status.

126 Materials and Methods

127 **Computing environment**

All analyses were done on a MacBook Pro laptop (x86_64-apple-darwin15.6.0 (64-bit)
Running under: macOS Mojave 10.14.6) using R version 4.0.2 (2020-06-22) and RStudio
1.2.5033. Specific versions of the R packages can be found in the associated code which
contains renv.lock file listing all used packages and version numbers.

132 Cohort selection

133 Sputum Prediction

134

135 To remove the potential of confounding lung biomarkers due to prior history of TB, new

136 cases of TB with CXRs containing radiologist annotations as well as sputum microscopy test

137 results from specimens prior to or on the treatment start date were selected. Those cases where 138 the specimen collection date was within 14 days of a CXR were included. For cases where 139 multiple pairs of specimens and CXRs existed, the last specimen prior to treatment was used. 140 For cases where multiple microscopy test results were present for a specimen, the last 141 microscopy test result for that specimen was used. For cases where multiple images existed, the 142 last imaging date was used. Unknown or non-standard microscopy results such as "Unknown 143 data" and "Saliva" were excluded. Code used for generating the cohort is provided in the Data 144 availability and code section. Ultimately, 572 new cases were selected from the database with 145 sputum microscopy results of Negative, 1 to 9 in 100 (1-9/100), 10 to 99 in 100 (1+), 1 to 9 in 1 146 (2+), 10 to 99 in 1 (3+), and More than 99 in 1 (4+) consisting of 259, 29, 144, 60, 58, and 22 147 cases respectively within this cohort. The cohort characteristics summarizing case details for the 148 sputum prediction cohort can be found in Supplementary Table 1. 149 Analysis of Timika Score with regards to other case characteristics in TB portals 150 For Figure 1 and Figure 2 visualizing the Timika Score in relation to other case 151 characteristics, we used all available images with manual radiologist annotations from the 152 February 2021 release of TB Portals data available for download from Aspera. This included 153 2058 images from 1761 cases covering not just New cases but all other types in the database. 154 The characteristics summarizing corresponding case details for the set of available images for the 155 Timika Score visualizations can be found in Supplementary Table 2.

156 Data preprocessing and extraction of feature set

Data from TB portals was downloaded as a list of .csv files from the Aspera file share service using the February 2021 version of each respective file. The CXR manual annotations are provided as a set of features corresponding to observations by radiologists within each

160 sextant of the lungs (dividing each lung by 1/3) as well as a set of features provided at the level 161 of the entire lung. For those features corresponding to sextant level observations, features where 162 no observations were provided by radiologists were imputed as 0 (for numerical data 163 corresponding to between 0-100% involvement of sextant) or "No" (for categorical data 164 indicating presence/absence of a specific feature within the sextant). The omission of these at 165 either the level of the entire sextant or specific sextant-level feature are interpreted as the 166 radiologist did not observe the feature.

167 After imputation, features were converted for tidy-like data processing using packages 168 from the R tidyverse. This permits various types of downstream feature engineering such as 169 identification of involvement of one or both lungs by sextant-level feature type, calculation of 170 summary statistics for numerical features across sextants, and other score calculations such as 171 Timika Score. For this analysis, involvement of both lungs as well as mean percentage of 172 sextant involvement across all sextants by specific sextant-level radiologist observation was 173 calculated along with Timika Score. Both lung features were calculated in a binary manner 174 where involvement of a left and right sextant for the features was required to indicate 175 involvement of both lungs for that feature. Timika Score was calculated like the original 176 publication (15) by a simple method of taking the overall abnormal percent of volume of the 177 lungs reported by the radiologist and adding 40 if the presence of cavity was indicated in the 178 radiologist report. Characteristics of derived features by microscopy status can be found in 179 Supplementary Table 3.

MLR3 framework was used to define a set of prediction tasks as well as pipelines for modeling (17). 70% of the data was selected as a training set and 30% was held out as a validation set. We tested two distinct prediction tasks in the MLR3 framework: 1) to predict

183	sputum positive (1 to 9 in 100, 1+, or higher) compared to negative and 2) to predict higher
184	bacterial load positive (2+, 3+, or higher) compared to negative. The positive to negative
185	prediction task was relatively well balanced between classes; however, the high bacterial load
186	positive to negative prediction task showed moderate class imbalancing so a class balancing step
187	was included in some pipelines for comparison. Machine learning (ML) pipelines using all
188	derived radiological features were compared to pipelines using only the Timika Score for
189	prediction. For ML pipelines using all derived radiological features, factor data was encoded to
190	a binary indicator (<u>https://mlr3pipelines.mlr-org.com/reference/mlr_pipeops_encode.html</u>), low
191	variance features were removed (<u>https://mlr3pipelines.mlr-</u>
192	org.com/reference/mlr_pipeops_removeconstants.html), features were scaled by min-max
193	scaling (<u>https://mlr3pipelines.mlr-org.com/reference/mlr_pipeops_scalerange.html</u>), and the top
194	5 features were selected via a variety of feature selection methods (<u>https://mlr3filters.mlr-</u>
195	org.com/) or Principal Component Analysis (https://mlr3pipelines.mlr-
196	org.com/reference/mlr_pipeops_pca.html). The following ML models were assessed as part of
197	the pipelines: featureless, glmnet, kknn, multinom, naïve bayes, rpart, ranger, xgboost, svm, and
198	nnet as described in the subsequent link (<u>https://mlr3learners.mlr-org.com/reference/index.html</u>).
199	For pipelines using only Timika score, only the min-max scaling step was included as part of the
200	pipeline.
201	Model performance benchmarking

5-fold cross validation was used to assess various binary classification metrics towards
respective prediction tasks on the training set. Both the metrics and the resampling strategies can
be found in the mlr3 documentation (<u>https://mlr3.mlr-org.com/reference/index.html</u>) under
Measures and Resampling Strategies sections. We also assess these binary classification metrics

in the validation dataset to ascertain performance on data which has never been used during model training. To compare performance of the top radiologist observations and Timika Score, the best pipelines using the top radiologist derived features were compared by bootstrapping without replacement (N = 200) to the best pipelines using Timika Score alone, or a featureless pipeline as a control to indicate the density of observed model performance particular to this dataset that may be due to random chance.

212 Calculation of inferential statistics

213 To estimate the univariate Odds Ratios (OR) and multivariate adjusted Odds Ratios 214 (AOR), the finalfit R package was used. Both hugenodule1 feature was removed from the 215 analysis as it did not show any variance. As Timika Score is highly correlated with other 216 variables in the dataset (e.g. overall abnormal volume and cavity), MRMR feature selection (https://mlr3filters.mlr-org.com/reference/mlr_filters_mrmr.html) was performed for the top 5 217 218 features to include in the multivariate modeling. As both_hugenodule1 feature was excluded, less 219 than 5 features were selected in the multivariate modeling. The both lungs feature was included 220 in the multivariate model to adjust for indication of involvement of both lungs from sextant level 221 features when assessing estimated odds of sputum positivity.

222 Visualization of Timika Score with other case attributes

Interesting case variables were examined for association with Timika Score to assess consistency with current understanding of TB clinical risk factors. This included demographic information such as age and BMI as well as case resistance status, case definition, and treatment outcome. The initial CXR with available radiologist observations were selected for each case,

Timika Score calculated and plotted using ggplot2 to visualize associations with other caseattributes.

229 For calculating temporal changes in Timika Score, those cases with an initial CXR 230 identified above were filtered for cases with an additional follow up CXR with radiologist 231 observation. The log2 transformed relative change were calculated for each image's Timika 232 Score comparing the earliest score with all subsequent scores. To account for differences in the 233 length of time between images that may impact the relative score change, the difference in 234 number of days between CXRs was calculated and the log2 transformed relative changes were 235 divided by the number of days between pairs of images for each case to generate the log2 236 relative change by day.

237 Data availability and code

238 The TB portals program necessitates all users of the data sign a DUA before access to the 239 underlying, de-identified clinical data is provided and the data can be requested at the following 240 URL (https://tbportals.niaid.nih.gov/download-data). Therefore, this study provides the code to 241 reproduce the analysis without the underlying raw data 242 (https://github.com/niaid/tbportals.xray.sputum.2021) in compliance with the DUA. To rerun the 243 analysis, interested parties can request data access by completing the DUA and then place the 244 downloaded files to the subdirectory of the data folder as provided in the GitHub repo 245 instructions. To aid reproducibility, the list of patient IDs and condition IDs used from the 246 sputum prediction analysis are provided in Supplementary Table 4. The specific record 247 identifiers for the set of images used for visualization of Timika Score in comparison with other 248 case attributes are provided in Supplementary Table 5. For cases where change in Timika was 249 calculated over time, the first and last images used in the case are shown along with the dates of

the image. Both supplementary tables allow those interested in examining the specific records to
do so after completion of required DUA irrespective of the evolution in number of available
cases in the database.

253 **Results**

Timika score associates with case clinical characteristics, disease

255 severity, and risk

256 The TB portals resource contains case information bridging across domains of interest 257 such as clinical, demographic, radiologic, and pathogen genomics. We leveraged the unique 258 value of these connections to assess any scores or other features of interest from the derived 259 radiological data. After generating the Timika Scores from all available CXRs with associated 260 radiologist annotations, we explored the relationship between Timika Score with the additional 261 information contained about the case mentioned above. We analyzed these relationships to 262 determine if they are consistent with prior TB clinical findings to assess the plausibility of the 263 derived radiological data.

Age, BMI, Type of Resistance, Case Definition, and Case Outcome show

265 associations with Timika Scores

We used only the initial image with associated radiologist observations for the visualizations assessing Timika Score in relation to other aspects of the case. We visualize Timika Score with age of onset, BMI, resistance type, case definition, and case outcome and include a trendline in the relationships for any numerical features. We identify relationships

between Timika score and case characteristics of interest that are consistent with our priorknowledge of TB clinical risk.

272	For instance, Timika Score of the initial image gradually increases with age of onset until
273	the relationship plateaus around age 50 and decreases although some of the decrease and initial
274	increase can likely be attributed to the lower density of observations at the two extremes of age
275	(Fig 1A). Timika Score decreases with increasing BMI until it plateaus around a BMI of ~25
276	(Fig 1B). Like age, the extremes of the BMI visualization need to be interpreted cautiously
277	given the lower densities. XDR cases, resistant to the most TB drugs and with the worst
278	outcomes, are observed to have a higher median Timika Score and interquartile range compared
279	to other case resistance types (Fig 1C). New cases of TB are shown to have a lower median
280	Timika Score and interquartile range compared to other types of cases such as Chronic TB, Prior
281	treatment failure, Relapse, Prior lost to follow up, or Other prior unknown status case definitions
282	(Fig 1D). Similarly, visualizing case outcomes reveals that detrimental treatment outcomes such
283	as Died, Treatment failure, Lost to follow up, or Unknown show higher median Timika Scores
284	compared to beneficial outcomes such as Treatment completion, Cured, or Still on treatment (Fig
285	1E). Taken together, the results demonstrate associations between Timika Score from initial
286	available image and case characteristics that reflects TB clinical risk.

287 Fig 1 Association of Timika Score from initial CXR with radiologist observations with other case attributes. Timika Score derived from initial available CXRs associated with cases 288 289 in the TB Portals repository are visualized along with a variety of salient case characteristics 290 with missing observations dropped according to variable (N = 1757). For A) and B), the age of 291 onset (N = 1757) and BMI (N = 1268) from the case are shown with blue trend line respectively. 292 For C), D), and E), boxplots with interguartile range showing Timika Score by the type of drug 293 resistance, status of case at start, and status of case at end are shown. In C), MDR non XDR (N =294 752), Mono DR (N = 118), Poly DR (N = 78), Sensitive (N = 514), and XDR (N = 295) case 295 drug resistance statuses are shown with the associated Timika Score from initial CXR with the 296 case. XDR cases tend to show relatively higher Timika Scores. In D), Chronic TB (N = 18), 297 Failure (N = 179), Lost to follow up (N = 65), New (N = 1141), Other (N = 45), Relapse (N = (N = 1141)) 298 304), and Unknown (N = 5) case definitions are shown with the associated Timika Score from

299 initial CXR with the case. Undesirable case definitions such as Failure, Lost to follow up,

300 Relapse, Chronic TB, or Unknown from prior history show higher Timika Score compared to

301 New cases. In E), Completed (N = 170), Cured (N = 984), Died (N = 126), Failure (N = 128),

302 Lost to follow up (N = 151), Still on treatment (N = 169), and Unknown (N = 29) case outcomes

are shown with the associated Timika Score from initial CXR with the case. Undesirable

304 outcomes such as Died, Failure, Lost to follow up, or Unknown show higher Timika Score

305 compared to beneficial outcomes such as Completed, Cured, or Still on treatment.

306 Age, BMI, Type of Resistance, Case Definition, and Case Outcome show

307 associations with the temporal changes in Timika Scores

308 Of those cases with initial CXR images visualized above, we next examined changes in 309 Timika Score whenever follow up CXR images were available. To do so, we filter on cases with 310 this additional imaging information. We calculate log2 transformed Timika Score from initial 311 image to last available image per case dividing by the number of days between images to account 312 for the relative amount of time between each image. We use ggplot2 to visualize log2 313 transformed change in Timika Score by day with age of onset, BMI, resistance type, case 314 definition, and case outcome and include a trend line in the associations for any numerical 315 features. Interestingly, most cases have a negative relative change in Timika Score by day 316 indicating improvement in lung status over the course of the case. Such a decrease over time 317 would be expected given these cases would have been undergoing clinical management. We 318 observed associations between the relative change by day and case characteristics of interest that 319 are consistent with prior knowledge of TB clinical risk.

For instance, the log2 transformed change in Timika Score by day steadily decreases with age of onset such that younger age shows greater relative change whereas older age shows less relative change (Fig 2A). Conversely, log2 transformed change in Timika Score by day increases as BMI increases (Fig 2B). Lower BMI demonstrates a smaller relative change as compared to higher BMI. When examining relative change by resistance type of the case, Drug

- 325 sensitive cases are observed to have a larger relative change compared to drug resistant types
- 326 (Fig 2C). Similarly, new cases of TB show greater relative change compared to other types of
- 327 cases such as Prior treatment failure, Prior lost to follow up, Relapse, or Other prior status at the
- 328 start of the case (Fig 2D). Visualizing by case outcomes demonstrates that undesirable outcomes
- 329 such as Died, Treatment failure, or Lost to follow up show decreased relative change by day
- 330 compared to beneficial outcomes such as Treatment completion or Cured (Fig 2E). Like earlier
- 331 visualizations of the Timika Score from available initial image, observations of relative changes
- are consistent our prior understanding of TB clinical risk factors.

333 Fig 2 Association of relative change in Timika Score by day from initial CXR with 334 radiologist observations to last available CXR with radiologist observations with other case 335 attributes. Log2 relative change in Timika Score by day from initial available CXR to last 336 available CXR associated with cases in the TB Portals repository are visualized along with a 337 variety of salient case characteristics with missing observations dropped according to variable (N 338 = 297). For A) and B), the age of onset (N = 297) and BMI (N = 292) from the case are 339 visualized with log2 relative change in Timika Score by day with blue trend line respectively. 340 To aid in visualizing the trendline, the y axis was limited to between -0.1 and 0.1 resulting in an 341 additional 9 outliers being removed for age of onset and BMI case numbers above respectively. 342 For C), D), and E), boxplots with interquartile range showing log2 relative change in Timika 343 Score by day compared by the type of drug resistance, status of case at start, and status of case at 344 end are shown. In C), MDR non XDR (N = 160), Mono DR (N = 13), Poly DR (N = 1), 345 Sensitive (N = 24), and XDR (N = 99) case drug resistance statuses are shown with the log2 346 relative change in Timika Score by day from initial CXR to last available CXR. To aid in 347 visualization, y axis was limited to -0.1, and 0.1 resulting in additional 5, 2, 0, 2, and 0 outliers 348 being removed from MDR non XDR, Mono DR, Poly DR, Sensitive, and XDR case numbers 349 above respectively. In general, drug resistant cases show lower relative change in Timika Score 350 although several groups show low N and must be interpreted cautiously. In D), Failure (N = 35), 351 Lost to follow up (N = 8), New (N = 184), Other (N = 4), and Relapse (N = 66) case definitions 352 are shown with the log2 relative change in Timika Score by day from initial CXR to last 353 available CXR. To aid in visualization, y axis was limited to -0.1, and 0.1 resulting in additional 354 0, 0, 8, 1, and 0 outliers being removed from Failure, Lost to follow up, New, Other, and Relapse 355 case numbers above respectively. Deleterious case definitions such as Failure, Lost to follow up, 356 Relapse, or Other from prior history show less change in relative Timika Score compared to New 357 cases. In E), Completed (N = 27), Cured (N = 223), Died (N = 15), Failure (N = 10), Lost to 358 follow up (N = 20), Still on treatment (N = 1), and Unknown (N = 1) case outcomes are shown 359 with the log2 relative change in Timika Score from initial CXR to last available CXR. To aid in 360 visualization, y axis was limited to -0.1, and 0.1 resulting in additional 4, 5, 0, 0, 0 and 0 outliers 361 being removed from Completed, Cured, Died, Failure, Lost to follow up, Still on treatment, and Unknown case numbers above respectively. Deleterious outcomes such as Died, Failure, Lost to 362

follow up, or Unknown show smaller relative changes compared to beneficial outcomes such as
 Completed and Cured. As above for other visualizations, caution is warranted given the small
 N's associated with certain subgroups.

366

367 Sputum smear microscopy results associate with Timika score in this cohort

- 368 of TB portals cases
- 369 We next assessed the previously reported role of Timika Score for predicting sputum
- 370 smear status by analyzing the selected cohort of new cases having microscopy results from
- 371 sputum specimens taken prior to treatment with associated images within two weeks of the
- 372 specimen (N = 572). Mean Timika Score is lowest amongst new cases with a sputum microscopy
- 373 result of negative and increases for microscopy results indicating a higher burden of bacteria
- 374 within sputum [1 to 9 in 100, 1+, 2+, etc.] (Fig 3). Only the 4+ level shows slightly lower mean
- 375 Timika Score compared to the next highest level of 3+, which may be due to variance from the
- lower number of available cases in this 4+ level (N = 22). This clear trend in the TB portals
- 377 dataset is consistent with previously reported role of Timika Score for predicting baseline
- 378 sputum status.

379 Fig 3 Timika score derived from radiologist observations of CXR within two weeks of 380 specimen taken prior to treatment start. Timika score is visualized by the smear microscopy 381 results of specimens taken prior to treatment start for which CXRs were available within two 382 weeks of specimen date (N = 572). Boxplots show median Timika Score for associated images 383 with interquartile range. Images associated with negative smear microscopy status have lower 384 Timika Scores while those with positive statuses (1 to 9 in 100, 1+, and higher) show 385 progressively higher Timika Scores that appear to plateau around 2+ or higher. The following 386 number of Timika Scores derived from radiologist observations of images are available for 387 Negative, 1 to 9 in 100 (1–9/100), 10 to 99 in 100 (1+), 1 to 9 in 1 (2+), 10 to 99 in 1 (3+), and 388 More than 99 in 1 (4+) groups respectively: 259, 29, 144, 60, 58, 22. 389

390 Inferential statistics associated with sputum microscopy status

391 Given the association of Timika Score with sputum smear microscopy, we continued our 392 investigation by assessing the risk of a positive sputum microscopy status (1 to 9 in 100, 1+, or 393 higher) compared to a negative status using Timika score along with the other derived features 394 from radiologist observations. To do so, we performed univariate and multivariate logistic 395 regression removing any feature with no variance that caused univariate or multivariate modeling 396 to fail. We leveraged MRMR feature selection to select the top 5 features for multivariate 397 models. Timika Score is derived from the radiological features (e.g., presence of cavity and 398 overall abnormal volume) so we wanted to select additional features that would not directly 399 correlate with Timika Score but still potentially correlate with sputum microscopy status.

400 We observe multiple features with evidence of involvement of both lungs showing higher 401 risk of sputum microscopy positivity including calcified nodules, fibrotic nodules, low density 402 nodules, involvement of both lungs by indication of any type of sextant feature, medium density 403 nodules, medium cavities, small cavities, multiple cavities, and small nodules (Table 1). For 404 numeric variables, large cavities, low density nodules, medium cavities, small cavities, and 405 overall percent of abnormal volume showed statistically significant increases in risk of positive 406 sputum result (active pathogen detected in the sputum) per each unit increase in percentage 407 whereas pleural effusion percent of hemithorax involved showed the opposite. Each unit 408 increase in Timika Score showed an increased risk in pre-treatment sputum positive microscopy 409 status consistent with its prior reported role. In the multivariate model, the Timika Score showed 410 a higher risk of positive sputum microscopy status after adjusting for indication of involvement 411 of both lungs. This suggests that risk of positive sputum microscopy status does not require 412 evidence of both lung involvement but rather greater percentage abnormal regions or cavity area

- 413 may be sufficient for the increased risk indicated by Timika Score. Interestingly, the other
- 414 MRMR selected features of the multivariate model were all indicators of involvement of both
- 415 lungs for the respective features. Only the indication of calcified nodules in both lungs
- 416 demonstrated a statistically significant increase in risk of positive sputum microscopy status
- 417 adjusting for other covariates in the multivariate model. This feature could suggest cases with
- 418 unreported prior history of pulmonary TB.

419 **Table 1. Risk of positive sputum status (1+ or higher) by univariate or multivariate logistic**

- regression analysis on derived features from radiologist observations of CXRs within two
 weeks of specimens taken prior to treatment.
- 422

Dependent: event2		Nega	Positi	OR (univariable)	OR
•		tive	ve		(multivariable)
aremediastinallymphnodespr	no	233 (4	289 (5	-	-
esent		4.6)	5.4)		
	yes	26 (52	24 (48	0.74 (0.41-	-
		.0)	.0)	1.33, p=0.319)	
both_calcnod	no	241 (4	270 (5	-	-
		7.2)	2.8)		
	yes	18 (29	43 (70	2.13 (1.22-	2.14 (1.14-
		.5)	.5)	3.88, p=0.010)	4.13, p=0.020)
both_calcsequella1	no	254 (4	299 (5	-	-
		5.9)	4.1)		
	yes	5 (26.	14 (73	2.38 (0.90-	-
		3)	.7)	7.44, p=0.101)	
both_clustnod	no	229 (4	281 (5	-	-
		4.9)	5.1)		
	yes	30 (48	32 (51	0.87 (0.51-	-
		.4)	.6)	1.48, p=0.603)	
both_collapse1	no	259 (4	311 (5	-	-
		5.4)	4.6)		
	yes	0 (0.0)	2 (100	1764014.84 (0.00-	1485353.66 (0.00-
			.0)	NA, p=0.982)	NA, p=0.981)
both_fibroticnodule1	no	201 (4	214 (5	-	-
		8.4)	1.6)		
	yes	58 (36	99 (63	1.60 (1.10-	-
		.9)	.1)	2.35, p=0.014)	
both_highden1	no	257 (4	304 (5	-	-

		5.8)	4.2)		
	yes	2 (18.	9 (81.	3.80 (0.97-	-
	,	2)	8)	25.10, p=0.089)	
both_isanylargecavitymult	no	259 (4	311 (5	-	-
_ , , , ,		5.4)	4.6)		
	yes	0 (0.0)	2 (100	1764014.84 (0.00-	-
			.0)	NA, p=0.982)	
both_largecavity1	no	259 (4	312 (5	-	-
		5.4)	4.6)		
	yes	0 (0.0)	1 (100	646864.01 (0.00-	1056464.82 (0.00-
			.0)	NA, p=0.980)	NA, p=0.987)
both_largenodule1	no	257 (4	308 (5	-	-
-		5.5)	4.5)		
	yes	2 (28.	5 (71.	2.09 (0.45-	-
		6)	4)	14.65, p=0.382)	
both_lowden1	no	231 (4	256 (5	-	-
		7.4)	2.6)		
	yes	28 (32	57 (67	1.84 (1.14-	-
		.9)	.1)	3.02, p=0.014)	
both_lowgroundglassdensity	no	193 (4	226 (5	-	-
active freshnodules 1		6.1)	3.9)		
	yes	66 (43	87 (56	1.13 (0.78-	-
		.1)	.9)	1.64, p=0.534)	
both_lungs	no	149 (5	136 (4	-	-
		2.3)	7.7)		
	yes	110 (3	177 (6	1.76 (1.27-	0.87 (0.57-
		8.3)	1.7)	2.46, p=0.001)	1.31, p=0.504)
both_medden1	no	231 (4	262 (5	-	-
		6.9)	3.1)		
	yes	28 (35	51 (64	1.61 (0.99-	-
		.4)	.6)	2.66, p=0.060)	
both_mediumcavity1	no	258 (4	304 (5	-	-
		5.9)	4.1)		
	yes	1 (10.	9 (90.	7.64 (1.42-	-
		0)	0)	141.33, p=0.055)	
both_mediumnodule1	no	229 (4	272 (5	-	-
		5.7)	4.3)		
	yes	30 (42	41 (57	1.15 (0.70-	-
		.3)	.7)	1.92, p=0.584)	
both_multiplecavitiesbeseen	no	256 (4	298 (5	-	-
		6.2)	3.8)		
	yes	3 (16.	15 (83	4.30 (1.40-	-
		7)	.3)	18.69, p=0.022)	

both_multnod	no	220 (4	249 (5	-	-
		6.9)	3.1)		
	yes	39 (37	64 (62	1.45 (0.94-	-
		.9)	.1)	2.26, p=0.096)	
both_noncalcnod	no	200 (4	223 (5	-	-
		7.3)	2.7)		
	yes	59 (39	90 (60	1.37 (0.94-	-
		.6)	.4)	2.01, p=0.106)	
both_smallcavity1	no	253 (4	287 (5	-	-
		6.9)	3.1)		
	yes	6 (18.	26 (81	3.82 (1.65-	-
		8)	.2)	10.39, p=0.004)	
both_smallnodule1	no	180 (4	188 (5	-	-
		8.9)	1.1)		
	yes	79 (38	125 (6	1.51 (1.07-	-
		.7)	1.3)	2.15, p=0.019)	
ispleuraleffusionbilateral	no	257 (4	312 (5	-	-
		5.2)	4.8)		
	yes	2 (66.	1 (33.	0.41 (0.02-	-
		7)	3)	4.32, p=0.470)	
mean_calcsequella	Mean	0.1 (0.	0.2 (0.	1.20 (0.90-	-
	(SD)	3)	8)	1.83, p=0.316)	
mean_collapse	Mean	0.3 (3.	0.3 (2.	1.00 (0.93-	-
	(SD)	2)	1)	1.07, p=0.938)	
mean_fibroticnodule	Mean	2.2 (3.	2.4 (3.	1.02 (0.97-	-
	(SD)	6)	8)	1.06, p=0.505)	
mean_highden	Mean	0.2 (0.	0.5 (3.	1.08 (0.98-	-
	(SD)	8)	1)	1.27, p=0.225)	
mean_hugenodule	Mean	0.0 (0.	0.0 (0.	0.87 (0.35-	-
	(SD)	2)	2)	2.04, p=0.729)	
mean_largecavity	Mean	0.1 (1.	0.6 (2.	1.18 (1.05-	-
	(SD)	2)	6)	1.38, p=0.015)	
mean_largenodule	Mean	0.2 (0.	0.1 (0.	0.93 (0.71-	-
	(SD)	6)	8)	1.18, p=0.532)	
mean_lowden	Mean	2.7 (4.	4.6 (6.	1.07 (1.04-	-
	(SD)	3)	6)	1.11, p<0.001)	
mean_lowgroundglassdensit	Mean	4.7 (8.	4.6 (7.	1.00 (0.98-	-
yactive freshnodules	(SD)	7)	4)	1.02, p=0.948)	
mean_medden	Mean	2.3 (5.	3.0 (5.	1.02 (0.99-	-
	(SD)	4)	9)	1.06, p=0.150)	
mean_mediumcavity	Mean	0.3 (1.	1.1 (2.	1.28 (1.15-	-
	(SD)	2)	7)	1.46, p<0.001)	
mean_mediumnodule	Mean	1.9 (4.	1.4 (3.	0.96 (0.92-	-

	(SD)	0)	2)	1.01, p=0.107)	
mean_smallcavity	Mean	0.4 (1.	1.2 (2.	1.40 (1.23-	-
	(SD)	1)	4)	1.61, p<0.001)	
mean_smallnodule	Mean	4.9 (8.	5.7 (8.	1.01 (0.99-	-
	(SD)	3)	0)	1.03, p=0.265)	
othernontbabnormalities	no	217 (4	260 (5	-	-
		5.5)	4.5)		
	yes	42 (44	53 (55	1.05 (0.68-	-
		.2)	.8)	1.65, p=0.819)	
overall_timika	Mean	30.9 (47.9 (1.02 (1.01-	1.02 (1.01-
	(SD)	26.6)	30.2)	1.03, p<0.001)	1.03, p<0.001)
overallpercentofabnormalvol	Mean	22.1 (26.6 (1.01 (1.00-	-
ume	(SD)	18.2)	18.7)	1.02, p=0.004)	
pleuraleffusionpercentofhem	Mean	1.9 (7.	0.8 (4.	0.96 (0.93-	-
ithoraxinvolved	(SD)	5)	1)	0.99, p=0.029)	

423

424 Odds ratios and adjusted odds ratios from univariate and multivariate logistic regression analysis 425 on derived features from radiologist observations of images taken within two weeks of 426 specimens prior to treatment start. Shown are the individual derived features from radiologist 427 observations along with the summary statistics across the prediction categories of Negative or 428 Positive (1 to 9 in 100, 1+, or higher sputum smear microscopy status). Odds ratios with the 95% 429 confidence intervals with unadjusted P-values are shown for each derived feature for the 430 univariate and if applicable, multivariate models. The - sign shows reference categories in the 431 univariate Odds Ratio column or reference as well as excluded variables in the multivariate Odds 432 Ratio column.

433

434 Assessing predictive capacity of machine learning models

435 The TB portals offers a variety of radiologist observations of CXRs that may provide

436 additional information towards the prediction of baseline sputum smear microscopy status.

437 Therefore, we investigated the additional features comparing predictive performance to Timika

438 Score alone. By doing so, we sought to identify any additional features that might improve upon

439 Timika Score performance and to evaluate how well Timika Score itself could predict sputum

440 status when compared to various feature selection or dimensionality reduction techniques that

441 summarize the radiological features within the data.

442 Comparison of predicting 2+ versus 1+ sputum smear status in training and

443 validation sets

444 We noted that sputum smear scores of 2+ or greater showed a higher mean Timika Score 445 so we tried two predictive approaches: task one involved predicting positive (1 to 9 in 100, 1+, or 446 greater smear status indicating any active pathogen in the sputum) versus negative smear status 447 while task two involved predicting higher bacterial load positive (2+, 3+, or greater smear status) 448 versus negative sputum status. We split the data into a 70% training set and 30% validation set 449 for the model training and validation. All pipelines were created and run using the MLR3 450 package which allows for unbiased assessment of model performance by encapsulating the pre-451 processing steps within the cross-validation approach. All prediction tasks included featureless 452 pipelines showing a non-informative model that only predicts the most prevalent class or 453 randomly selects a class in case of a tie. Thus, the featureless model can be considered a control 454 and predictive models should perform significantly better than this featureless control model. 455 In the first prediction problem attempting to discriminate positive from negative status, 5-456 fold cross validation results on the training data showed that most models demonstrated 457 relatively similar predictive performance across pipelines (Table 2). Pipelines using top 5 458 components by principal component analysis (which captured $\sim 50\%$ of variability in the dataset) 459 tended to show slightly decreased performance in general. Since this prediction problem did not 460 have a large class imbalance, the addition of a class balancing step did not make a significant 461 impact to prediction performance for the pipelines tested. Of note, pipelines only including the 462 Timika Score showed equivalent performance in general to workflows using the top 5 predictive 463 features from various feature selection algorithms. There is a slight decrease in performance of 464 Timika-only models to the best top 5 feature selection model, which reflect that additional

- 465 features may provide some minimal improvement over Timika Score. To test predictive
- 466 performance on data which the models had not seen before, we trained the above models on the
- 467 entire training set and tested on 30% of held out validation data (Table 3). We observed similar
- 468 findings to the cross-validated results we obtained from the training data.

469 Table 2. Comparison of machine learning pipeline performance via 5-fold cross-validation

- 470 for predicting positive (1 to 9 in 100, 1+, or higher) versus negative sputum microscopy
- 471 status on training data.

pipeline	classif.au	classif.mc	classif.sensit	classif.specif
	с	с	ivity	icity
ffact.cb.enc.zv.num_scale.flt.auc.classif.m	0.69 +/-	0.37 +/-	0.73 +/- 0.05	0.63 +/- 0.05
ultinom	0.02	0.02		
ffact.cb.enc.zv.num_scale.flt.auc.classif.lo	0.7 +/-	0.34 +/-	0.78 +/- 0.03	0.61 +/- 0.03
g_reg	0.02	0.05		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.69 +/-	0.33 +/-	0.69 +/- 0.04	0.66 +/- 0.09
f.ranger	0.03	0.03		
timika.num_scale.classif.rpart	0.7 +/-	0.32 +/-	0.51 +/- 0.23	0.75 +/- 0.08
	0.01	0.05		
timika.num_scale.cb.classif.rpart	0.67 +/-	0.32 +/-	0.62 +/- 0.07	0.65 +/- 0.08
	0.04	0.03		
ffact.cb.enc.zv.num_scale.flt.auc.classif.c	0.68 +/-	0.32 +/-	0.72 +/- 0.08	0.6 +/- 0.05
v_glmnet	0.03	0.02		
ffact.cb.enc.zv.num_scale.flt.auc.classif.gl	0.69 +/-	0.31 +/-	0.78 +/- 0.04	0.61 +/- 0.02
mnet	0.01	0.06		
ffact.cb.enc.zv.num_scale.flt.auc.classif.n	0.66 +/-	0.31 +/-	0.78 +/- 0.01	0.57 +/- 0.05
net	0.06	0.04		
ffact.enc.zv.num_scale.flt.njmim.classif.lo	0.7 +/-	0.31 +/-	0.75 +/- 0	0.6 +/- 0.08
g_reg	0.01	0.04		
ffact.enc.zv.num_scale.flt.njmim.classif.m	0.7 +/-	0.31 +/-	0.75 +/- 0	0.6 +/- 0.08
ultinom	0.01	0.04		
ffact.enc.zv.num_scale.flt.njmim.classif.ra	0.68 +/-	0.31 +/-	0.53 +/- 0.12	0.74 +/- 0.04
nger	0.04	0.02		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.68 +/-	0.31 +/-0	0.68 +/- 0.05	0.63 +/- 0.05
f.svm	0.01			
ffact.cb.enc.zv.num_scale.flt.auc.classif.sv	0.66 +/-	0.3 +/-	0.73 +/- 0.05	0.51 +/- 0.08
m	0.01	0.04		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.67 +/-	0.3 +/-	0.69 +/- 0.08	0.6 +/- 0.05
cv_glmnet	0.02	0.04		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.65 +/-	0.3 +/-	0.76 +/- 0.07	0.56 +/- 0.02
f.log_reg	0.03	0.04		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.69 +/-	0.3 +/-	0.81 +/- 0.01	0.42 +/- 0.07

f.naive_bayes	0.05	0.04		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.69 +/-	0.3 +/-	0.75 +/- 0.04	0.55 +/- 0.05
f.multinom	0.02	0.03		
timika.num_scale.cb.classif.log_reg	0.67 +/-	0.29 +/-	0.69 +/- 0.11	0.6 +/- 0.05
	0.02	0.03		
timika.num_scale.cb.classif.multinom	0.67 +/-	0.29 +/-	0.69 +/- 0.11	0.6 +/- 0.05
	0.02	0.03		
timika.num_scale.classif.naive_bayes	0.67 +/-	0.29 +/-	0.69 +/- 0.12	0.6 +/- 0.08
	0.02	0.03		
$ffact.cb.enc.zv.num_scale.pca.classif.nnet$	0.62 +/-	0.28 +/-	0.58 +/- 0.08	0.77 +/- 0.11
	0.09	0.09		
ffact.cb.enc.zv.num_scale.flt.auc.classif.n	0.71 +/-	0.28 +/-	0.83 +/- 0.08	0.39 +/- 0.06
aive_bayes	0.04	0.06		
ffact.cb.enc.zv.num_scale.flt.auc.classif.r	0.64 +/-	0.28 +/-	0.68 +/- 0.19	0.6 +/- 0.21
part	0.06	0.04		
ffact.enc.zv.num_scale.flt.njmim.classif.sv	0.66 +/-	0.27 +/-	0.56 +/- 0.02	0.68 +/- 0.05
m	0.01	0.09		
ffact.cb.enc.zv.num_scale.pca.classif.svm	0.67 +/-	0.27 +/-	0.59 +/- 0.02	0.6 +/- 0.17
	0.03	0.08		
timika.num_scale.classif.kknn	0.64 +/-	0.27 +/-	0.75 +/- 0.08	0.5 +/- 0.02
	0.03	0.08		
ffact.cb.enc.zv.num_scale.pca.classif.mul	0.71 +/-	0.27 +/-	0.76 +/- 0.07	0.49 +/- 0
tinom	0.02	0.05		
timika.num_scale.classif.log_reg	0.67 +/-	0.27 +/-	0.56 +/- 0.08	0.66 +/- 0.03
	0.02	0.05		
timika.num_scale.classif.multinom	0.67 +/-	0.27 +/-	0.56 +/- 0.08	0.66 +/- 0.03
	0.02	0.05		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.66 +/-	0.27 +/-	0.68 +/- 0.05	0.58 +/- 0.07
xgboost	0.03	0.03		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.66 +/-	0.27 +/-	0.72 +/- 0.08	0.55 +/- 0.08
ranger	0.01	0.02		
timika.num_scale.cb.classif.naive_bayes	0.67 +/-	0.27 +/-	0.72 +/- 0.04	0.56 +/- 0.03
	0.02	0.02		
timika.num_scale.classif.xgboost	0.66 +/-	0.27 +/-	0.61 +/- 0.08	0.63 +/- 0.02
	0.04	0.01		
ffact.cb.enc.zv.num_scale.flt.auc.classif.ra	0.61 +/-	0.26 +/-	0.61 +/- 0.08	0.63 +/- 0.03
nger	0.02	0.17		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.65 +/-	0.26 +/-	0.69 +/- 0.08	0.6 +/- 0.1
svm	0.02	0.07		
timika.num_scale.classif.svm	0.65 +/-	0.26 +/-	0.61 +/- 0.12	0.65 +/- 0.07
	0.03	0.07		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.66 +/-	0.26 +/-	0.69 +/- 0.04	0.6 +/- 0.1
multinom	0.03	0.06		

ffact.enc.zv.num_scale.flt.njmim.classif.gl	0.7 +/-	0.26 +/-	0.61 +/- 0.08	0.65 +/- 0.12
mnet	0.01	0.20 +7-	0.01 +/- 0.08	0.03 +/- 0.12
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.01	0.26 +/-	0.67 +/- 0.12	0.6 +/- 0.07
rpart	0.01 +/-	0.20 +7-	0.07 +7- 0.12	0.0 +/- 0.0/
timika.num_scale.classif.nnet	0.66 +/-	0.26 +/-	0.69 +/- 0.08	0.56 +/- 0.01
	0.00 +/-	0.20 +7-	0.05 +7- 0.08	0.50 +/- 0.01
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.62	0.26 +/-	0.69 +/- 0.08	0.6 +/- 0.05
glmnet	0.04 +/-	0.03	0.05 +7- 0.08	0.0 +7- 0.05
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.68 +/-	0.26 +/-	0.69 +/- 0.11	0.6 +/- 0.05
f.cv_glmnet	0.03	0.03	0.05 17 0.11	0.0 17 0.05
timika.num_scale.cb.classif.nnet	0.67 +/-	0.26 +/-	0.72 +/- 0.04	0.56 +/- 0.07
	0.01	0.03	0.72 77 0.04	0.50 17 0.07
timika.num_scale.cb.classif.svm	0.68 +/-	0.26 +/-	0.69 +/- 0.08	0.6 +/- 0.05
	0.01	0.03	0.05 17 0.00	0.0 17 0.05
ffact.enc.zv.num_scale.flt.njmim.classif.n	0.69 +/-	0.05 +/-	0.78 +/- 0.13	0.55 +/- 0.2
aive_bayes	0.01	0.1	0.70 7 0.13	0.33 17 0.2
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.65 +/-	0.25 +/-	0.65 +/- 0.06	0.53 +/- 0.09
f.nnet	0.04	0.09	0.03 .7 0.00	0.00 17 0.00
ffact.cb.enc.zv.num_scale.pca.classif.log_	0.69 +/-	0.24 +/-	0.75 +/- 0.08	0.48 +/- 0.02
reg	0.08	0.06	0.75 .7 0.00	0.10 . , 0.02
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.65 +/-	0.24 +/-	0.69 +/- 0.08	0.51 +/- 0.03
nnet	0.02	0.05		,
ffact.enc.zv.num_scale.flt.njmim.classif.c	0.68 +/-	0.24 +/-	0.56 +/- 0.04	0.68 +/- 0.2
v_glmnet	0.03	0.04	,	,
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.65 +/-	0.24 +/-	0.69 +/- 0.08	0.6 +/- 0.05
log_reg	0.01	0.02		
ffact.cb.enc.zv.num_scale.pca.classif.kkn	0.65 +/-	0.24 +/-	0.61 +/- 0.04	0.63 +/- 0.03
n	0.03	0.02		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.64 +/-	0.23 +/-	0.64 +/- 0.16	0.53 +/- 0.12
f.kknn	0.05	0.08		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.66 +/-	0.23 +/-	0.64 +/- 0.08	0.58 +/- 0.08
f.glmnet	0.02	0.02		
ffact.enc.zv.num_scale.flt.njmim.classif.rp	0.65 +/-	0.22 +/-	0.44 +/- 0.08	0.73 +/- 0.06
art	0.06	0.13		
ffact.enc.zv.num_scale.flt.njmim.classif.k	0.64 +/-	0.22 +/-	0.67 +/- 0.04	0.58 +/- 0.05
knn	0.06	0.11		
ffact.cb.enc.zv.num_scale.pca.classif.ran	0.62 +/-	0.22 +/-	0.56 +/- 0.12	0.63 +/- 0.08
ger	0.05	0.1		
timika.num_scale.cb.classif.kknn	0.63 +/-	0.21 +/-	0.73 +/- 0.01	0.44 +/- 0.07
	0.03	0.04		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.67 +/-	0.2 +/-	0.67 +/- 0.09	0.56 +/- 0.12
f.xgboost	0.05	0.19		
ffact.cb.enc.zv.num_scale.pca.classif.glm	0.7 +/-	0.2 +/-	0.75 +/- 0.04	0.49 +/- 0.02

net	0.08	0.11		
timika.num_scale.classif.ranger	0.64 +/-	0.2 +/-	0.59 +/- 0.11	0.63 +/- 0.05
timka.hum_scule.clussi.hunger	0.04 17	0.11	0.55 17 0.11	0.03 17 0.03
timika.num_scale.cb.classif.ranger	0.6 +/-	0.19 +/-	0.65 +/- 0.07	0.55 +/- 0.03
	0.09	0.13		
ffact.cb.enc.zv.num_scale.flt.auc.classif.x	0.6 +/-	0.19 +/-	0.7 +/- 0.03	0.51 +/- 0.07
gboost	0.01	0.03	,	,
ffact.enc.zv.num_scale.flt.njmim.classif.x	0.61 +/-	0.18 +/-	0.57 +/- 0.14	0.63 +/- 0.05
gboost	0.05	0.05		
timika.num_scale.cb.classif.xgboost	0.62 +/-	0.17 +/-	0.57 +/- 0.06	0.53 +/- 0.02
	0.06	0.12		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.63 +/-	0.16 +/-	0.53 +/- 0.12	0.63 +/- 0.14
f.rpart	0.03	0.14		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.58 +/-	0.16 +/-	0.75 +/- 0.08	0.37 +/- 0.1
kknn	0.02	0.03		
ffact.enc.zv.num_scale.flt.njmim.classif.n	0.66 +/-	0.15 +/-	0.49 +/- 0.1	0.7 +/- 0.02
net	0.07	0.11		
ffact.cb.enc.zv.num_scale.pca.classif.xgb	0.62 +/-	0.13 +/-	0.53 +/- 0.04	0.58 +/- 0.02
oost	0.04	0.16		
ffact.cb.enc.zv.num_scale.flt.auc.classif.k	0.61 +/-	0.12 +/-	0.58 +/- 0.04	0.51 +/- 0.03
knn	0.07	0.08		
ffact.cb.enc.zv.num_scale.pca.classif.rpar	0.57 +/-	0.12 +/-	0.53 +/- 0.04	0.58 +/- 0.03
t	0	0.08		
ffact.cb.enc.zv.num_scale.pca.classif.naiv	0.55 +/-	0.1 +/-	0.86 +/- 0.04	0.23 +/- 0.06
e_bayes	0.06	0.18		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.65 +/-	0.1 +/-	1 +/- 0	0.02 +/- 0.03
naive_bayes	0.01	0.15		
ffact.cb.enc.zv.num_scale.pca.classif.cv_g	0.59 +/-	0.09 +/-	0.64 +/- 0.16	0.41 +/- 0.05
Imnet	0.13	0.17		
ffact.cb.enc.zv.num_scale.pca.classif.feat	0.5 +/- 0	0.09 +/-	0.57 +/- 0.02	0.52 +/- 0.05
ureless		0.02		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.5 +/- 0	0.05 +/-	0.56 +/- 0.1	0.53 +/- 0.05
featureless		0.09		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.5 +/- 0	0.03 +/-	0.53 +/- 0.08	0.56 +/- 0.1
f.featureless		0.09	0	1.4.0
ffact.enc.zv.num_scale.flt.njmim.classif.fe	0.5 +/- 0	0 +/- 0	0 +/- 0	1 +/- 0
atureless	05./0	0		1,/0
timika.num_scale.classif.featureless	0.5 +/- 0	0 +/- 0	0 +/- 0	1 +/- 0
timika.num_scale.cb.classif.featureless	0.5 +/- 0	-0.12 +/-	0.36 +/- 0.12	0.52 +/- 0.09
fferstels and musicipal de la 166		0.04	0.42 . / 0.00	0.45 . / 0.05
ffact.cb.enc.zv.num_scale.flt.auc.classif.fe	0.5 +/- 0	-0.02 +/-	0.43 +/- 0.06	0.45 +/- 0.05
atureless		0.03		

- 473 The machine learning pipeline is shown in the pipeline column. Model performance metrics
- 474 include Area under the curve (classif.auc), Balanced accuracy (classif.bacc), Matthew's
- 475 Correlation Coefficient (classif.mcc), Sensitivity (classif.sensitivity), and Specificity
- 476 (classif.specificity). Each cell represents the median metric +/- the MAD for the 5-fold cross
- 477 validation testing on the training data representing 70% of the entire dataset. Pipelines using only
- the Timika Score for prediction start with Timika in the pipeline name. Each pipeline shows all
- 479 steps used in the pipeline ending with the machine learning algorithm used and are ordered by
- 480 classif.mcc.
- 481

482 **Table 3. Comparison of machine learning pipeline performance for predicting positive (1 to**

483 **9** in 100, 1+, or higher) versus negative sputum microscopy status on validation data.

484

pipeline	classif.a	classif.mc	classif.sensit	classif.specif
	uc	C	ivity	icity
timika.num_scale.classif.rpart	0.66905	0.3686316	0.6533333	0.71578947
	26	25		
timika.num_scale.cb.classif.rpart	0.66905	0.3686316	0.6533333	0.71578947
	26	25		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.l	0.66533	0.3426355	0.7333333	0.61052632
og_reg	33	61		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.67747	0.3300229	0.76	0.56842105
multinom	37	46		
timika.num_scale.classif.naive_bayes	0.65649	0.3290517	0.72	0.61052632
	12	73		
timika.num_scale.cb.classif.log_reg	0.65649	0.3290517	0.72	0.61052632
	12	73		
timika.num_scale.cb.classif.multinom	0.65649	0.3290517	0.72	0.61052632
	12	73		
timika.num_scale.cb.classif.svm	0.65494	0.3290517	0.72	0.61052632
	74	73		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.65649	0.3290517	0.72	0.61052632
cv_glmnet	12	73		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.r	0.66526	0.3290517	0.72	0.61052632
part	32	73		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.65382	0.3290517	0.72	0.61052632
svm	46	73		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.r	0.67389	0.3260949	0.7466667	0.57894737
anger	47	51		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.65080	0.3200582	0.76	0.55789474
multinom	7	31		
timika.num_scale.classif.nnet	0.65649	0.3188608	0.72	0.6
	12	49		
ffact.enc.zv.num_scale.flt.njmim.classif.lo	0.68343	0.3188608	0.72	0.6

g_reg	86	49		
ffact.enc.zv.num_scale.flt.njmim.classif.m	0.68343	0.3188608	0.72	0.6
ultinom	86	49		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.64807	0.3160651	0.7466667	0.56842105
glmnet	02	51		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.68414	0.3101006	0.76	0.54736842
glmnet	04	39		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.65396	0.3101006	0.76	0.54736842
nnet	49	39		
ffact.cb.enc.zv.num_scale.flt.auc.classif.lo	0.68315	0.3052985	0.7066667	0.6
g_reg	79	67		
ffact.cb.enc.zv.num_scale.flt.auc.classif.sv	0.64322	0.3052985	0.7066667	0.6
m	81	67		
ffact.cb.enc.zv.num_scale.flt.auc.classif.gl	0.68526	0.3020841	0.6933333	0.61052632
mnet	32	6		
ffact.cb.enc.zv.num_scale.flt.auc.classif.rp	0.69536	0.3020841	0.6933333	0.61052632
art	84	6		
timika.num_scale.cb.classif.xgboost	0.66764	0.2985495	0.72	0.57894737
	91	67		
ffact.cb.enc.zv.num_scale.flt.auc.classif.m	0.68154	0.2950861	0.7066667	0.58947368
ultinom	39	36		
ffact.enc.zv.num_scale.flt.njmim.classif.nn	0.68336	0.2901905	0.56	0.72631579
et	84			
ffact.cb.enc.zv.num_scale.flt.auc.classif.cv	0.67214	0.2884210	0.72	0.56842105
_glmnet	04	53		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.66701	0.2884210	0.72	0.56842105
cv_glmnet	75	53		0 5 4 7 9 4 9 4 9
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.65985	0.2820708	0.7333333	0.54736842
log_reg	96	94	0.700000	0 5 4 7 9 4 9 4 9
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.66940	0.2820708	0.7333333	0.54736842
svm	35	94	0.70	0 5 5 7 0 0 4 7 4
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.66722	0.2783051	0.72	0.55789474
kknn	81	73	0 700007	0 5 6 0 4 0 1 0 5
timika.num_scale.classif.ranger	0.65319	0.2747216	0.7066667	0.56842105
	3	68	0.700007	0.50040105
ffact.cb.enc.zv.num_scale.flt.auc.classif.ra	0.66694	0.2747216	0.7066667	0.56842105
nger ffact chiang zvinum, scala nea classif rang	74 0.67024	68 0.2712772	0.5866667	0.68421053
ffact.cb.enc.zv.num_scale.pca.classif.rang	56	65	0.300007	0.00421033
er ffact.enc.zv.num_scale.flt.njmim.classif.na	0.67838	0.2645800	0.8	0.45263158
ive_bayes	0.07838	0.2645800	0.8	0.43203130
ffact.cb.enc.zv.num_scale.pca.classif.log_r	0.66631	0.2619571	0.7333333	0.52631579
	58	0.2019571	0.7 555555	0.320313/9
eg	20	0		

timika.num_scale.classif.xgboost	0.63726	0.2610956	0.6933333	0.56842105
	32	07		
ffact.enc.zv.num_scale.flt.njmim.classif.kk	0.67607	0.2602752	0.76	0.49473684
nn	02	47		
timika.num_scale.cb.classif.naive_bayes	0.65649	0.2580948	0.72	0.53684211
	12	68		
timika.num_scale.classif.svm	0.63221	0.2517322	0.6	0.65263158
	05	49		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.65656	0.2499759	0.8133333	0.42105263
naive_bayes	14	12		
timika.num_scale.cb.classif.nnet	0.65649	0.2479921	0.72	0.52631579
	12	39		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.64463	0.2460671	0.6266667	0.62105263
nnet	16	29		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.62301	0.2454016	0.56	0.68421053
rpart	75	78		
ffact.enc.zv.num_scale.flt.njmim.classif.rp	0.68603	0.2388899	0.2933333	0.89473684
art	51	24		
timika.num_scale.classif.log_reg	0.65649	0.2386959	0.5866667	0.65263158
	12	84		
timika.num_scale.classif.multinom	0.65649	0.2386959	0.5866667	0.65263158
	12	84		
ffact.enc.zv.num_scale.flt.njmim.classif.cv	0.67614	0.2386959	0.5866667	0.65263158
_glmnet	04	84		
ffact.enc.zv.num_scale.flt.njmim.classif.sv	0.67319	0.2386959	0.5866667	0.65263158
m	3	84		
timika.num_scale.cb.classif.ranger	0.66084	0.2372960	0.68	0.55789474
	21	08		
ffact.cb.enc.zv.num_scale.flt.auc.classif.kk	0.62736	0.2340389	0.6666667	0.56842105
nn	84	47		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.64238	0.2324484	0.5466667	0.68421053
xgboost	6	72		
timika.num_scale.classif.kknn	0.66477	0.2313835	0.84	0.36842105
	19	79		
ffact.enc.zv.num_scale.flt.njmim.classif.gl	0.68470	0.2303696	0.6	0.63157895
mnet	18	5		
ffact.cb.enc.zv.num_scale.flt.auc.classif.xg	0.63298	0.2270658	0.68	0.54736842
boost	25	68		
timika.num_scale.cb.classif.kknn	0.65410	0.2254002	0.8266667	0.37894737
	53	87		
ffact.cb.enc.zv.num_scale.flt.auc.classif.nn	0.65578	0.2237619	0.6666667	0.55789474
et _	95	99		

ost	81	21		
ffact.cb.enc.zv.num_scale.flt.auc.classif.na	0.68175	0.2194435	0.7866667	0.42105263
ive_bayes	44	61		
ffact.enc.zv.num_scale.flt.njmim.classif.ra	0.68287	0.2029143	0.4933333	0.70526316
nger	72	11		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.66828	0.1974496	0.5333333	0.66315789
ranger	07	26		
ffact.cb.enc.zv.num_scale.pca.classif.svm	0.67838	0.1974496	0.5333333	0.66315789
	6	26		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.62484	0.1934603	0.5066667	0.68421053
xgboost	21	33		
ffact.cb.enc.zv.num_scale.pca.classif.multi	0.66856	0.1861667	0.68	0.50526316
nom	14	9		
ffact.cb.enc.zv.num_scale.pca.classif.glmn	0.64007	0.1839688	0.7733333	0.4
et	02	35		
ffact.cb.enc.zv.num_scale.pca.classif.rpart	0.60385	0.1826171	0.4133333	0.75789474
	96	34		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.71873	0.1793498	0.84	0.31578947
kknn	68	07		
ffact.cb.enc.zv.num_scale.pca.classif.kknn	0.62154	0.1692777	0.4933333	0.67368421
	39	92		
ffact.cb.enc.zv.num_scale.pca.classif.naive	0.63557	0.1639286	0.8533333	0.28421053
_bayes	89	56		
ffact.cb.enc.zv.num_scale.pca.classif.nnet	0.63291	0.1557765	0.3866667	0.75789474
	23	62		
ffact.cb.enc.zv.num_scale.pca.classif.cv_gl	0.63866	0.1396394	0.7333333	0.4
mnet	67	61		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.f	0.5	0.1303167	0.5733333	0.55789474
eatureless		53		
ffact.enc.zv.num_scale.flt.njmim.classif.xg	0.61466	0.1009750	0.4133333	0.68421053
boost	67	8		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.5	0.0915197	0.5866667	0.50526316
featureless		08		
ffact.cb.enc.zv.num_scale.pca.classif.featu	0.5	0.0592348	0.5333333	0.52631579
reless		88		
timika.num_scale.classif.featureless	0.5	0	0	1
ffact.enc.zv.num_scale.flt.njmim.classif.fe	0.5	0	0	1
atureless				
ffact.cb.enc.zv.num_scale.flt.auc.classif.fe	0.5	-	0.5466667	0.45263158
atureless		0.0006999		
		88		
timika.num_scale.cb.classif.featureless	0.5	-	0.4533333	0.53684211
		0.0097895		

		88		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.65789	-	0.9866667	0.01052632
naive_bayes	47	0.0129261		
		12		

485

The machine learning pipeline is shown in the pipeline column. Model performance metrics include Area under the curve (classif.auc), Balanced accuracy (classif.bacc), Matthew's Correlation Coefficient (classif.mcc), Sensitivity (classif.sensitivity), and Specificity (classif.specificity). Each cell represents the metric for the performance on the 30% held-out validation test set after training on the 70% training data. Pipelines using only the Timika Score for prediction start with Timika in the pipeline name. Each pipeline shows all steps used in the pipeline ending with the machine learning algorithm used and are ordered by classif.mcc.

494 We hypothesized that the second prediction task might demonstrate a performance boost 495 in predictive power since the 2+ sputum status or higher (very high pathogen load in the sputum) 496 showed a larger difference in Timika Score compared to negative. For this prediction task, we 497 removed the borderline 1 to 9 in 100 and 1+ sputum test results from the analysis. 5-fold cross 498 validation results on training set confirmed our hypothesis as we observed increases in 499 performance for reported metrics (Table 4) for both top 5 features pipelines as well as Timika 500 Score only workflows. In general, we observed equivalent performance from Timika Score only 501 pipelines to workflows using the top 5 predictive features from various feature selection 502 algorithms. The benchmarking suggests that while possible to achieve additional gains from the 503 set of derived radiologist observations, these would likely be minimal. Interestingly, though this 504 prediction problem shows a moderate class imbalance, the incorporation of class balancing did 505 not significantly increase or impair performance for the pipelines. When we tested models 506 trained on the entire training set on a validation set of 30% held out data, we saw similar 507 predictive performance to our observation of the 5-fold cross-validated results on the training set 508 (Table 5).

509 Table 4. Comparison of machine learning pipeline performance via 5-fold cross-validation

510 for predicting high bacterial load positive (2+ or higher) versus negative sputum

511 microscopy status on training data.

512

pipeline	classif.au c	classif.mc c	classif.sensit ivity	classif.specif icity
timika.num_scale.cb.classif.naive_bayes	0.77 +/-	0.5 +/-	0.72 +/- 0.04	0.74 +/- 0.13
	0.06	0.09		
ffact.enc.zv.num_scale.flt.njmim.classif.ra	0.78 +/-	0.49 +/-	0.84 +/- 0.05	0.65 +/- 0.15
nger	0.07	0.09		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.76 +/-	0.48 +/-	0.75 +/- 0.04	0.7 +/- 0.07
f.glmnet	0.06	0.1		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.78 +/-	0.48 +/-	0.81 +/- 0	0.7 +/- 0.07
f.multinom	0.04	0.1		
$ffact.cb.enc.zv.num_scale.flt.mrmr.classif.$	0.75 +/-	0.47 +/-	0.69 +/- 0.08	0.75 +/- 0.07
cv_glmnet	0.05	0.14		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.77 +/-	0.47 +/-	0.69 +/- 0.08	0.75 +/- 0.1
f.cv_glmnet	0.04	0.14		
timika.num_scale.cb.classif.log_reg	0.77 +/-	0.47 +/-	0.69 +/- 0.08	0.75 +/- 0.07
	0.06	0.14		
timika.num_scale.cb.classif.multinom	0.77 +/-	0.47 +/-	0.69 +/- 0.08	0.75 +/- 0.07
	0.06	0.14		
timika.num_scale.cb.classif.svm	0.74 +/-	0.47 +/-	0.69 +/- 0.08	0.75 +/- 0.07
	0.05	0.14		
timika.num_scale.classif.nnet	0.77 +/-	0.47 +/-	0.75 +/- 0.03	0.68 +/- 0.08
	0.06	0.12		
ffact.cb.enc.zv.num_scale.flt.auc.classif.gl	0.75 +/-	0.47 +/-	0.75 +/- 0.04	0.7 +/- 0.15
mnet	0.08	0.06		
ffact.cb.enc.zv.num_scale.flt.auc.classif.lo	0.75 +/-	0.44 +/-	0.81 +/- 0.03	0.65 +/- 0.15
g_reg	0.03	0.16		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.74 +/-	0.44 +/-	0.76 +/- 0.07	0.63 +/- 0.2
f.nnet	0.06	0.11		
ffact.cb.enc.zv.num_scale.flt.auc.classif.n	0.77 +/-	0.44 +/-	0.72 +/- 0.12	0.74 +/- 0.16
net	0.04	0.07		
ffact.cb.enc.zv.num_scale.flt.auc.classif.r	0.75 +/-	0.43 +/-	0.69 +/- 0.04	0.8 +/- 0.15
part	0.09	0.23		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.7 +/-	0.43 +/-	0.69 +/- 0.08	0.75 +/- 0.02
glmnet	0.08	0.15		
ffact.cb.enc.zv.num_scale.flt.auc.classif.m	0.75 +/-	0.42 +/-	0.75 +/- 0.04	0.7 +/- 0.1
ultinom	0.06	0.19		
ffact.cb.enc.zv.num_scale.flt.auc.classif.sv	0.73 +/-	0.42 +/-	0.75 +/- 0.04	0.7 +/- 0.1
m	0.06	0.19		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.78 +/-	0.42 +/-	0.78 +/- 0.04	0.7 +/- 0.18

f.log_reg	0.04	0.19		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.75 +/-	0.42 +/-	0.72 +/- 0.08	0.75 +/- 0.07
f.svm	0.04	0.16	,	
timika.num_scale.cb.classif.nnet	0.72 +/-	0.41 +/-	0.69 +/- 0.04	0.74 +/- 0.09
-	0.07	0.1		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.78 +/-	0.41 +/-	0.72 +/- 0.07	0.68 +/- 0.1
f.ranger	0.06	0.02		
ffact.cb.enc.zv.num_scale.flt.auc.classif.ra	0.73 +/-	0.4 +/-	0.67 +/- 0.03	0.75 +/- 0.07
nger	0.11	0.17		
ffact.cb.enc.zv.num_scale.pca.classif.ran	0.74 +/-	0.37 +/-	0.65 +/- 0.06	0.75 +/- 0.02
ger	0.04	0.06		
ffact.cb.enc.zv.num_scale.flt.auc.classif.n	0.74 +/-	0.36 +/-	0.81 +/- 0.05	0.5 +/- 0.07
aive_bayes	0.03	0.14		
ffact.enc.zv.num_scale.flt.njmim.classif.lo	0.75 +/-	0.36 +/-	0.89 +/- 0	0.5 +/- 0.07
g_reg	0.06	0.14		
ffact.enc.zv.num_scale.flt.njmim.classif.m	0.75 +/-	0.36 +/-	0.89 +/- 0	0.5 +/- 0.07
ultinom	0.06	0.14		
timika.num_scale.cb.classif.ranger	0.7 +/-	0.36 +/-	0.69 +/- 0.04	0.58 +/- 0.16
	0.08	0.08		
timika.num_scale.classif.svm	0.75 +/-	0.36 +/-	0.81 +/- 0.04	0.5 +/- 0.12
	0	0.06		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.67 +/-	0.35 +/-	0.68 +/- 0.05	0.7 +/- 0.13
multinom	0.13	0.26		0.60 / 0.10
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.66 +/-	0.35 +/-	0.69 +/- 0.04	0.68 +/- 0.12
log_reg	0.1	0.2	0.00 / 0.00	07 (007
ffact.cb.enc.zv.num_scale.flt.auc.classif.c	0.72 +/-	0.35 +/-	0.69 +/- 0.08	0.7 +/- 0.07
v_glmnet	0.07	0.19	0.96 . / 0.04	
ffact.enc.zv.num_scale.flt.njmim.classif.sv m	0.78 +/- 0.04	0.35 +/- 0.19	0.86 +/- 0.04	0.5 +/- 0.15
m ffact.cb.enc.zv.num_scale.flt.mrmr.classif.			0.75 +/- 0.08	0.74 +/- 0.02
nnet	0.66 +/- 0.07	0.35 +/-	0.73 +7- 0.08	0.74 +7- 0.02
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.07	0.17	0.72 +/- 0.04	0.8 +/- 0.06
f.rpart	0.02	0.17	0.72 77 0.04	0.0 17 0.00
timika.num_scale.cb.classif.kknn	0.02	0.34 +/-	0.75 +/- 0.07	0.6 +/- 0.11
	0.08	0.1	0.75 7 0.07	0.0 17 0.11
ffact.enc.zv.num_scale.flt.njmim.classif.gl	0.75 +/-	0.34 +/-	0.86 +/- 0.03	0.45 +/- 0.04
mnet	0.06	0.09	0.00 ., 0.03	0.15 .7 0.01
ffact.enc.zv.num_scale.flt.njmim.classif.rp	0.7 +/-	0.34 +/-	0.78 +/- 0.09	0.47 +/- 0.11
art	0.04	0.08	,	,
timika.num_scale.classif.ranger	0.68 +/-	0.34 +/-	0.78 +/- 0.03	0.53 +/- 0.04
_ 5	0.05	0.01	, -	
timika.num_scale.cb.classif.xgboost	0.73 +/-	0.33 +/-	0.61 +/- 0.04	0.63 +/- 0.08
_ 5	0.03	0.11		-

ffact.cb.enc.zv.num_scale.flt.auc.classif.k knn	0.73 +/- 0.05	0.33 +/- 0.01	0.7 +/- 0.03	0.63 +/- 0.03
	0.65 +/-	0.01	0.81 +/- 0.07	0.5 +/- 0.04
ffact.enc.zv.num_scale.flt.njmim.classif.n net	0.03 +/-	0.32 +/-	0.81 +/- 0.0/	0.3 +/- 0.04
timika.num_scale.classif.rpart	0.69 +/-	0.15	0.81 +/- 0.12	0.53 +/- 0.08
timika.hum_scale.classil.rpart	0.09 +7-	0.32 +/-	0.81 +/- 0.12	0.55 +/- 0.08
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.68 +/-	0.1	0.75 +/- 0.11	0.65 +/- 0.11
	0.08 +/-	0.31 +/-	0.75 +7- 0.11	0.03 +/- 0.11
ranger ffact.enc.zv.num_scale.flt.njmim.classif.k	0.14	0.10	0.84 +/- 0.03	0.45 +/- 0.2
· · ·	0.72 +7-	0.06	0.84 +7- 0.03	0.43 +/- 0.2
knn timika.num_scale.classif.xgboost	0.72 +/-	0.31 +/-	0.83 +/- 0.07	0.47 +/- 0.04
timika.hum_scale.classil.xgb00st	0.72 +7-	0.03	0.85 +7- 0.07	0.47 +7- 0.04
ffact ch and tw num acala fit mrmr classif				
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.71 +/- 0.07	0.3 +/- 0.3	0.72 +/- 0.08	0.7 +/- 0.05
svm ffact.cb.enc.zv.num_scale.pca.classif.nnet	0.65 +/-	0.3 +/-	0.57 +/- 0.1	0.68 +/- 0.1
hact.cb.enc.zv.hum_scale.pca.classh.hhet	0.03 +7-	0.3 +/-	0.37 +7- 0.1	0.08 +/- 0.1
timika.num_scale.classif.kknn	0.72 +/-	0.17	0.92 +/- 0	0.37 +/- 0.08
	0.72 +7-	0.5 +/- 0.1	0.92 +7-0	0.57 +7- 0.08
ffact.cb.enc.zv.num_scale.flt.auc.classif.x	0.1	0.3 +/-	0.72 +/- 0.08	0.7 +/- 0.07
gboost	0.12	0.08	0.72 +7- 0.08	0.7 +7- 0.07
9	0.12	0.08	0.67 +/- 0.04	0.65 +/- 0.11
timika.num_scale.cb.classif.rpart	0.71 +7-	0.29 +/-	0.07 +7- 0.04	0.03 +/- 0.11
timika.num_scale.classif.log_reg	0.77 +/-	0.29 +/-	0.86 +/- 0.04	0.35 +/- 0.05
timika.hum_scale.classih.log_reg	0.06	0.25 +7-	0.00 +7- 0.04	0.55 +7- 0.05
timika.num_scale.classif.multinom	0.77 +/-	0.29 +/-	0.86 +/- 0.04	0.35 +/- 0.05
timika.hum_scale.classif.hutthom	0.06	0.25 17	0.00 7 0.04	0.55 17 0.05
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.71 +/-	0.28 +/-	0.58 +/- 0.06	0.75 +/- 0.06
rpart	0.05	0.06	0.00 17 0.00	0.75 77 0.00
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.72 +/-	0.27 +/-	0.83 +/- 0	0.45 +/- 0.15
f.naive_bayes	0.06	0.07	0.03 17 0	0.45 17 0.15
ffact.cb.enc.zv.num_scale.pca.classif.log_	0.74 +/-	0.26 +/-	0.69 +/- 0.08	0.5 +/- 0.04
reg	0.06	0.1	0.03 .7 0.00	0.5 7 0.01
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.7 +/-	0.25 +/-	0.69 +/- 0.04	0.58 +/- 0.23
xgboost	0.07	0.11	0.05 ., 0.01	0.50 . 7 0.25
timika.num_scale.classif.naive_bayes	0.77 +/-	0.25 +/-	0.86 +/- 0.04	0.35 +/- 0.05
	0.06	0.04		
ffact.cb.enc.zv.num_scale.pca.classif.cv_g	0.68 +/-	0.24 +/-	0.69 +/- 0.12	0.5 +/- 0.12
Imnet	0.13	0.2	,	,
ffact.enc.zv.num_scale.flt.njmim.classif.n	0.73 +/-	0.24 +/-	0.83 +/- 0.04	0.45 +/- 0.12
aive_bayes	0.06	0.04	, , , , , , , , , , , , , , , , , , , ,	,
ffact.cb.enc.zv.num_scale.pca.classif.kkn	0.65 +/-	0.24 +/-	0.65 +/- 0.03	0.65 +/- 0.07
n	0.02	0.02		
ffact.cb.enc.zv.num_scale.pca.classif.xgb	0.64 +/-	0.22 +/-	0.64 +/- 0.07	0.53 +/- 0.19

oost	0.07	0.17		
ffact.cb.enc.zv.num_scale.pca.classif.rpar	0.6 +/-	0.22 +/-	0.61 +/- 0.08	0.53 +/- 0.04
t	0.07	0.13		
ffact.cb.enc.zv.num_scale.pca.classif.svm	0.69 +/-	0.22 +/-	0.67 +/- 0.08	0.74 +/- 0.09
	0.13	0.12		
ffact.cb.enc.zv.num_scale.pca.classif.mul	0.73 +/-	0.21 +/-	0.69 +/- 0.04	0.47 +/- 0.04
tinom	0.1	0.12		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.68 +/-	0.21 +/-	0.69 +/- 0.12	0.6 +/- 0.11
f.xgboost	0.06	0.08		
ffact.enc.zv.num_scale.flt.njmim.classif.x	0.74 +/-	0.21 +/-	0.83 +/- 0.04	0.5 +/- 0.2
gboost	0.04	0.06		
ffact.cb.enc.zv.num_scale.pca.classif.glm	0.74 +/-	0.2 +/-	0.72 +/- 0.04	0.47 +/- 0.04
net	0.07	0.02		
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.65 +/-	0.19 +/-	0.67 +/- 0.08	0.55 +/- 0.04
f.kknn	0.1	0.07		
ffact.cb.enc.zv.num_scale.pca.classif.naiv	0.7 +/-	0.17 +/-	0.83 +/- 0.04	0.3 +/- 0.1
e_bayes	0.01	0.14		
ffact.enc.zv.num_scale.flt.njmim.classif.c	0.77 +/-	0.17 +/-	0.97 +/- 0.04	0.11 +/- 0.08
v_glmnet	0.06	0.14		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.63 +/-	0.15 +/-	0.72 +/- 0.12	0.42 +/- 0.04
kknn	0.12	0.14		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.72 +/-	0.1 +/-	0.94 +/- 0.08	0.16 +/- 0.23
naive_bayes	0.01	0.11		
ffact.cb.enc.zv.num_scale.pca.classif.feat	0.5 +/- 0	0.04 +/-	0.5 +/- 0.04	0.47 +/- 0.08
ureless		0.14		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.5 +/- 0	0.01 +/-	0.5 +/- 0.04	0.55 +/- 0.2
featureless		0.2		
ffact.enc.zv.num_scale.flt.njmim.classif.fe	0.5 +/- 0	0 +/- 0	1 +/- 0	0 +/- 0
atureless				
timika.num_scale.classif.featureless	0.5 +/- 0	0 +/- 0	1 +/- 0	0 +/- 0
ffact.cb.enc.zv.num_scale.flt.njmim.classi	0.5 +/- 0	-0.1 +/-	0.53 +/- 0.08	0.47 +/- 0.11
f.featureless		0.1		
timika.num_scale.cb.classif.featureless	0.5 +/- 0	-0.03 +/-	0.5 +/- 0.04	0.47 +/- 0.04
		0.05		
ffact.cb.enc.zv.num_scale.flt.auc.classif.fe	0.5 +/- 0	-0.02 +/-	0.47 +/- 0.12	0.5 +/- 0.15
atureless		0.23		

513

514 The machine learning pipeline is shown in the pipeline column. Model performance metrics

515 include Area under the curve (classif.auc), Balanced accuracy (classif.bacc), Matthew's

516 Correlation Coefficient (classif.mcc), Sensitivity (classif.sensitivity), and Specificity

517 (classif.specificity). Each cell represents the median metric +/- the MAD for the 5-fold cross

validation testing on the training data representing 70% of the entire dataset. Pipelines using only

- 519 the Timika Score for prediction start with Timika in the pipeline name. Each pipeline shows all
- 520 steps used in the pipeline ending with the machine learning algorithm used and are ordered by 521 classif.mcc.
- 522

523 Table 5. Comparison of machine learning pipeline performance for predicting high

- 524 bacterial load positive (2+ or higher) versus negative sputum microscopy status on
- 525 validation data.
- 526

pipeline	classif.a	classif.m	classif.sensiti	classif.specifi
	uc	сс	vity	city
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.72511	0.455404	0.7466667	0.72093023
log_reg	63	19		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.l	0.72387	0.441316	0.7333333	0.72093023
og_reg	6	61		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.72527	0.441316	0.7333333	0.72093023
multinom	13	61		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.72434	0.433969	0.7466667	0.69767442
multinom	11	04		
timika.num_scale.cb.classif.rpart	0.74108	0.427453	0.6533333	0.79069767
	53	16		
timika.num_scale.cb.classif.log_reg	0.71054	0.427426	0.72	0.72093023
5- 5	26	16		
timika.num_scale.cb.classif.multinom	0.71054	0.427426	0.72	0.72093023
	26	16		
timika.num_scale.cb.classif.nnet	0.71100	0.427426	0.72	0.72093023
	78	16		
timika.num_scale.cb.classif.svm	0.69813	0.427426	0.72	0.72093023
	95	16		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.c	0.71054	0.427426	0.72	0.72093023
v_glmnet	26	16		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.71054	0.427426	0.72	0.72093023
cv_glmnet	26	16		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.s	0.71271	0.427426	0.72	0.72093023
vm	32	16		
ffact.cb.enc.zv.num_scale.flt.auc.classif.rpa	0.74620	0.427066	0.76	0.6744186
rt	16	17		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.71875	0.419769	0.7333333	0.69767442
svm	97	12		
ffact.cb.enc.zv.num_scale.flt.auc.classif.log	0.75922	0.412539	0.7466667	0.6744186
_reg	48	25		
ffact.cb.enc.zv.num_scale.flt.auc.classif.mu	0.75426	0.412539	0.7466667	0.6744186
ltinom	36	25		
ffact.cb.enc.zv.num_scale.flt.auc.classif.nn	0.73689	0.412539	0.7466667	0.6744186
-----------------------------------------------	---------	----------	-------------------	------------
et	92	25	0.70	0.00707440
timika.num_scale.cb.classif.naive_bayes	0.71054	0.405770	0.72	0.69767442
	26	29	0.70	0.007(7442
ffact.cb.enc.zv.num_scale.flt.auc.classif.cv_	0.72914	0.405770	0.72	0.69767442
glmnet	73	29	0.70	0.00707440
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.r	0.72589	0.405770	0.72	0.69767442
anger	15	29	0 700000	0.0744100
ffact.cb.enc.zv.num_scale.flt.auc.classif.gl	0.73968	0.398233	0.7333333	0.6744186
mnet	99	97	0 7 2 2 2 2 2 2 2	0.0744100
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.71519	0.398233	0.7333333	0.6744186
glmnet	38	97	0.700000	0.0744400
ffact.cb.enc.zv.num_scale.flt.auc.classif.sv	0.69472	0.398233	0.7333333	0.6744186
m	87	97		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.n	0.67395	0.391957	0.7066667	0.69767442
net	35	6		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.k	0.73612	0.384348	0.76	0.62790698
knn	4	12		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.	0.72294	0.378316	0.6933333	0.69767442
glmnet	57	79		
ffact.cb.enc.zv.num_scale.flt.auc.classif.ran	0.71922	0.378316	0.6933333	0.69767442
ger	48	79		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.70480	0.378316	0.6933333	0.69767442
ranger	62	79		
ffact.cb.enc.zv.num_scale.flt.auc.classif.nai	0.74496	0.372004	0.7866667	0.58139535
ve_bayes	12	82		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.r	0.73317	0.366981	0.6133333	0.76744186
part	83	06		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.73891	0.361219	0.8133333	0.53488372
naive_bayes	47	78		
timika.num_scale.cb.classif.kknn	0.74899	0.356440	0.8266667	0.51162791
	22	32		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.72	0.348094	0.7466667	0.60465116
kknn		66		
ffact.cb.enc.zv.num_scale.flt.auc.classif.xg	0.74341	0.340846	0.72	0.62790698
boost	09	12		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.x	0.67798	0.338291	0.6533333	0.69767442
gboost	45	99		
timika.num_scale.cb.classif.ranger	0.69968	0.334571	0.6266667	0.72093023
	99	34		
ffact.enc.zv.num_scale.flt.njmim.classif.nai	0.73364	0.317888	0.8133333	0.48837209
ve_bayes	34	57		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.72263	0.316467	0.5333333	0.79069767

rpart	57	3		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.64418	0.312863	0.6933333	0.62790698
nnet	6	89		
timika.num_scale.classif.nnet	0.71054	0.311841	0.7333333	0.58139535
	26	2		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.70108	0.309081	0.6	0.72093023
xgboost	53	6		
ffact.cb.enc.zv.num_scale.pca.classif.glmn	0.70294	0.304999	0.7066667	0.60465116
et	57	56		
ffact.cb.enc.zv.num_scale.pca.classif.range	0.70914	0.303028	0.64	0.6744186
r	73	33		
ffact.enc.zv.num_scale.flt.njmim.classif.log	0.72031	0.301411	0.8	0.48837209
_reg	01	57		
ffact.enc.zv.num_scale.flt.njmim.classif.mu	0.72031	0.301411	0.8	0.48837209
ltinom	01	57		
ffact.enc.zv.num_scale.flt.njmim.classif.ran	0.72155	0.301411	0.8	0.48837209
ger	04	57		
timika.num_scale.classif.svm	0.68263	0.291544	0.7733333	0.51162791
	57	47		
ffact.cb.enc.zv.num_scale.pca.classif.cv_gl	0.69488	0.290082	0.7333333	0.55813953
mnet	37	01		
ffact.enc.zv.num_scale.flt.njmim.classif.kk	0.72077	0.285824	0.84	0.41860465
nn	52	35		
ffact.cb.enc.zv.num_scale.pca.classif.rpart	0.72217	0.277228	0.68	0.60465116
	05	81		
timika.num_scale.classif.log_reg	0.71054	0.273633	0.8133333	0.44186047
	26	04		
timika.num_scale.classif.multinom	0.71054	0.273633	0.8133333	0.44186047
	26	04		
timika.num_scale.classif.naive_bayes	0.71054	0.273633	0.8133333	0.44186047
	26	04		
ffact.enc.zv.num_scale.flt.njmim.classif.sv	0.71286	0.273633	0.8133333	0.44186047
m	82	04		
ffact.cb.enc.zv.num_scale.pca.classif.svm	0.71906	0.258798	0.64	0.62790698
	98	66		
ffact.enc.zv.num_scale.flt.njmim.classif.gl	0.72108	0.257010	0.8	0.44186047
mnet	53	37		
ffact.cb.enc.zv.num_scale.flt.auc.classif.kk	0.68573	0.253667	0.72	0.53488372
nn	64	46		
ffact.cb.enc.zv.num_scale.pca.classif.multi	0.70325	0.246224	0.7333333	0.51162791
nom	58	23		
ffact.cb.enc.zv.num_scale.pca.classif.kknn	0.63519	0.241785	0.6	0.65116279
	38	66		

timika.num_scale.classif.ranger	0.69426	0.240785	0.7866667	0.44186047
	36	07		
ffact.enc.zv.num_scale.flt.njmim.classif.xg	0.70325	0.240785	0.7866667	0.44186047
boost	58	07		
ffact.enc.zv.num_scale.flt.njmim.classif.rpa	0.67147	0.234748	0.8533333	0.34883721
rt	29	13		
timika.num_scale.cb.classif.xgboost	0.68093	0.232501	0.6133333	0.62790698
	02	03		
ffact.cb.enc.zv.num_scale.pca.classif.nnet	0.69023	0.231627	0.72	0.51162791
	26	91		
ffact.enc.zv.num_scale.flt.njmim.classif.cv_	0.70976	0.217485	0.9066667	0.25581395
glmnet	74	43		
ffact.enc.zv.num_scale.flt.njmim.classif.nn	0.66728	0.198541	0.8266667	0.34883721
et	68	5		
ffact.cb.enc.zv.num_scale.pca.classif.log_r	0.70387	0.197459	0.6666667	0.53488372
eg	6	88		
ffact.cb.enc.zv.num_scale.pca.classif.naive	0.67100	0.186109	0.8533333	0.30232558
_bayes	78	83		
timika.num_scale.classif.xgboost	0.70341	0.181277	0.8133333	0.34883721
	09	05		
timika.num_scale.classif.rpart	0.68682	0.171862	0.7866667	0.37209302
	17	41		
timika.num_scale.classif.kknn	0.70744	0.127279	0.8666667	0.23255814
	19	1		
ffact.cb.enc.zv.num_scale.flt.auc.classif.fea	0.5	0.097651	0.52	0.58139535
tureless		87		
ffact.cb.enc.zv.num_scale.pca.classif.featu	0.5	0.050307	0.5866667	0.46511628
reless		08		
ffact.cb.enc.zv.num_scale.pca.classif.xgbo	0.58046	0.049608	0.4933333	0.55813953
ost	51	19		
ffact.cb.enc.zv.num_scale.flt.mrmr.classif.n	0.71674	0.036994	0.9866667	0.02325581
aive_bayes	42	84		
ffact.cb.enc.zv.num scale.flt.mrmr.classif.f	0.5	0.027175	0.4933333	0.53488372
eatureless		29		
ffact.cb.enc.zv.num_scale.flt.njmim.classif.	0.5	0.011382	0.5466667	0.46511628
featureless		35		
timika.num_scale.classif.featureless	0.5	0	1	0
ffact.enc.zv.num_scale.flt.njmim.classif.fea	0.5	0	1	0
tureless	0.5	V	L	0
timika.num_scale.cb.classif.featureless	0.5	-	0.48	0.41860465
		0.097651		
		87		

The machine learning pipeline is shown in the pipeline column. Model performance metrics include Area under the curve (classif.auc), Balanced accuracy (classif.bacc), Matthew's Correlation Coefficient (classif.mcc), Sensitivity (classif.sensitivity), and Specificity (classif.specificity). Each cell represents the metric for the performance on the 30% held-out validation test set after training on the 70% training data. Pipelines using only the Timika Score for prediction start with Timika in the pipeline name. Each pipeline shows all steps used in the pipeline ending with the machine learning algorithm used and are ordered by classif.mcc.

535

536 Comparison of best performing feature selection and Timika-only models by

537 bootstrapping

Though our initial training and validation testing suggested that Timika Score only 538 539 pipelines showed minimal differences with the top 5 feature models, we wanted to further test 540 this for statistical significance. We chose the best performing class-balanced pipelines from the 541 5-fold cross validated results obtained from the training data. Thus, the best top 5 feature pipeline, Timika Score only pipeline, and a featureless pipeline were selected for further testing. 542 543 The featureless workflow is a control that would reveal the density of results expected due to 544 random chance regardless of any upstream preprocessing given that classes are balanced. We 545 perform a bootstrapping without replacement (N = 200) on the entire dataset using 70% of the 546 data for training and 30% for testing on each split.

547 The bootstrapping result on the prediction problem attempting to distinguish positive 548 from negative sputum results showed that the performance of the best top 5 feature pipeline was 549 slightly better than the Timika-only pipeline. Both showed significantly improved performance 550 from the workflow using a featureless model (Fig 4A). The bootstrapping on the prediction 551 problem attempting to distinguish higher bacterial load sputum results (2+ or higher compared to 552 negative) did not show any difference in performance for the best Timika-only pipeline 553 compared to the best top 5 workflow (Fig 4B). As before, both pipelines performed significantly

- better than the workflow using the featureless model. These results are consistent with the idea
- that Timika offers generally equivalent predictive performance to using the top 5 features from
- 556 the dataset. Inclusion of other features may offer minimal improvements in predictive
- 557 performance depending upon the model or set of features selected.

558 Fig 4. Comparison of best class-balanced pipelines via bootstrapping without replacement 559 (N = 200). The best class-balanced pipelines via 5-fold cross-validation performance on training 560 data were selected for comparison to assess using top 5 features via feature selection or 561 dimensionality reduction as compared to using only Timika Score. A featureless pipeline is used 562 as a control to show expected performance via random selection of outcome. Box plots with 563 interquartile range are overlaid on density plots showing the density of results of Matthew's 564 Correlation Coefficient across all bootstrapping results per pipeline. Performance is compared 565 across all groups by Kruskal-Wallis and by individual pairs using Wilcoxon test which are shown by the brackets. In A), the performance of the best pipelines for predicting positive (1 to 9 566 567 in 100, 1+, or higher) versus negative is shown whereas B) the performance of the best pipelines 568 for predicting high bacterial load positive (2+ or higher) versus negative is shown. Interestingly 569 there is a statistically significant difference between top 5 feature pipeline versus Timika Score 570 pipeline in A) and no significant difference in performance for Timika Score pipeline in B). This 571 shows that additional derived features from radiologist observations may result in small 572 performance gains although Timika Score alone provides generally equivalent prediction 573 performance for the identified best models.

574

575 **Discussion**

576 X ray imaging is a useful approach to diagnose and monitor disease progression and 577 status during routine TB clinical management. X ray imaging cannot discern the type of 578 resistance of tuberculosis as well as characterize the amount of pathogen in sputum, which only 579 microbiological methods can provide. These approaches assist clinicians with a more complete 580 understanding of the case and understanding their relationship is important. CXR is relatively 581 less expensive than other imaging modalities such as CT permitting its wider use especially in 582 LMIC that may face challenges with infrastructure cost to support routine CT use. Using CXRs, 583 radiologists can report on a variety of observations that determine lung biomarker status such as 584 overall abnormal volume of the lungs, presence of cavity, and presence of nodule, which the TB

585 Portals resource collects, standardizes, and provides as part of the patient record. Here we 586 investigated the previously reported Timika Score that can be derived from CXR radiologist 587 observations to characterize pre-treatment severity of disease. TB portals provides a unique real-588 world repository of TB cases, especially drug resistant cases to bridge across distinct domains 589 including radiological, pathogen genomic, microbiological, and clinical features; it is especially 590 suited to serve as a large reference resource for assessing derived scores like Timika Score for 591 testing in a real-world database of especially challenging TB cases. Our goal was to assess the 592 plausibility and utility of the derived Timika Score within this real-world resource by studying its 593 relationships to the other available case characteristics.

594 We demonstrate that Timika Score associates with other case characteristics consistent 595 with prior reporting of TB clinical risk factors. For instance, we show that images from patients with a lower BMI tended to have a higher Timika Score and less of a change from the initial 596 597 CXR to the last available CXR. TB and BMI have been reported to show a strongly logarithmic 598 association and there was reported fivefold increase in age-adjusted incidence of new pulmonary 599 TB in lowest BMI group compared to highest in a study of 1.7 million Norwegians (18, 19). In 600 the same report, Tverdal mention an interesting U-shaped association with BMI and all-cause 601 mortality which is strikingly like the U-shaped association we observed with Timika Score and 602 BMI. In our analysis, increasing age tended to associate with higher Timika Score and less of a 603 change from the initial CXR to the last available CXR. This is consistent with higher mortality, 604 morbidity, and risk of TB with increasing age especially since the symptoms of TB may be 605 confused with other age-related illnesses (20) resulting in delayed diagnosis or treatment. 606 Moreover, when comparing Timika Score with other clinical factors associated with the case, we 607 observe both higher Timika Scores and lower relative changes in Timika Score in cases with

higher-risk clinical factors (XDR, Relapse, etc.) or poor reported outcomes (e.g. Treatment
failure, Died, etc.). This is consistent with prior reports examining predictors that affect change
in radiological lesions over the course of treatment monitoring (13).

611 Finally, we demonstrated that Timika Score show a clear and statistically significant 612 predictive capacity for baseline, pre-treatment sputum microscopy status in the cohort of new 613 cases we identified from the TB Portals repository. This is important because the original reports 614 on Timika Score suggested the same association on a smaller dataset (15) that did not span 615 across the wide-range of participating sites from 14 countries. Taken together, these 616 observations support that the Timika Scores we are calculating reflect lung biomarker status 617 consistent with accumulated knowledge of the radiological and clinical associations in TB 618 disease.

619 This analysis has several limitations and caveats when interpreting results. The TB 620 Portals is a real-world data repository to better understand DR TB so it is challenging to separate 621 identified associations with other observed or unobserved variables from the case. Moreover, 622 respective images and test results for each case are not collected uniformly in time but rather as 623 clinical management of the case allows. We select cases for inclusion into the analysis cohort 624 based upon criteria we believe will accurately represent associations between images and 625 microbiological test results but we cannot rule out timing or other aspects of the case impacting 626 the associations we observe. For example, we noted both lungs involvement of calcified nodule 627 as showing higher risk of pre-treatment sputum positivity. Such a marker suggests a long-term 628 prior history of pulmonary TB that might not be reflected in the "New" case definition from 629 WHO. Collecting a prior history of chronic lung symptoms around the baseline sample 630 collectiong might allow us to see if the relationships we identified remain after stratifying by

these symptoms that could suggest a period of prior disease burden. Given these caveats, themodeling and visualizations need to be interpreted as hypothesis-generating.

633 A key goal of this study was to identify a risk score (either new or previously reported) 634 that could encapsulate a temporal snapshot of case dynamics relating to disease risk such as poor 635 outcome or infectiousness. The CXR derived Timika Score may provide a useful score in this 636 regard from the initial testing we performed. One caution with regards to the utility of Timika 637 Score from this analysis is that the risks and associations with sputum microscopy positivity 638 were calculated for samples taken prior to treatment. The dynamics of microbiological status in 639 sputum might not reflect the same dynamics of lung biomarkers in response to treatment. Given 640 these dynamics, applying the same risks from Timika Score for sputum positivity (i.e. presence 641 of pathogen in sputum) after treatment is not advisable and may require new approaches that 642 stratify by type of resistance and different treatment regimens. It also may require additional data 643 collection to support the requisite number of cases given the real-world nature of the resource 644 where only subsets of cases may meet the inclusion and exclusion criteria for analysis. 645 The temporal relationships between lung status (as observed in CXR images) and

646 bacterial pathogen load in the sputum (as observed by microscopy) are complex. For instance, at 647 the beginning of disease, radiological features may not be detectable in the lungs despite the 648 presence of bacteria in sputum. Meanwhile, towards the end of treatment, sputum may no longer 649 contain TB pathogen indicating a non-infectious case; however, the pathogen may remain in 650 certain areas of the lung such as cavities. Given these intricacies, additional research is 651 warranted to determine if improvements can be made in Timika Score to account for these 652 situations. Moreover, there may be limitations to the granularity of a clinical score like Timika 653 that can be generated from CXRs given the limitations of the modality with regards to imaging

detail. It may be necessary for other modalities such as CT to account for more complex features
such as the size of cavities, nodules or other aspects identified in the lung, which may not be
obvious on a CXR. The assessment of clinical scores such as Timika Score coming from these
various modalities is especially important for hard-to-treat cases such as MDR and XDR TB
where scores can be compared in the context of other features of the case.

659 We observed the best predictive performance in models predicting higher bacterial load 660 sputum status. This improvement in predictive performance for high bacterial load sputum 661 statuses (e.g. 2+ or higher) illustrates the nuances associated with predicting sputum status from 662 Timika Score. The borderline cases such as 1 to 9 in 100 or 1+ are more challenging to predict 663 as pathogen load is only slightly higher than the negative status specimens and furthermore some 664 negative samples may be false negatives. These false negatives may suffer from issues such as 665 sensitivity due to the challenges of acquiring a usable sputum sample. Despite these nuances, 666 our results confirm prior reported Timika Score utility for predicting baseline sputum positivity 667 albeit with better performance for high-bacterial load sputum samples. The high pathogen load 668 cases would also be among the most infectious and challenging to treat; therefore, we were 669 satisfied to observe the higher predictive performance in this clinically important group. We 670 believe that adding CXR-derived Timika Score to the TB Portals resource will open 671 opportunities to other researchers to utilize this score to understand TB in a real-world setting. 672 The score can serve as a reference from which to test against additional clinical scores that could 673 be derived from the available set of features captured in TB portals.

674 Acknowledgements

We would like to thank Qinlu Wang, Jingwen Gu, and Ziv Yaniv for helpful suggestions; the
MLR3 team for development of the MLR3 suite of packages. This research was supported in

- 677 part by the Office of Science Management and Operations (OSMO) of the NIAID. For their
- 678 contributions to the vision and requirements of TB Portals, we would like to thank: Mike
- 679 Tartakovsky, Darrell Hurt, Alina Grinev, and members of the TB Portals team.

680 **References**

681

682	1.	Dheda K, Barry CE, & Maartens G (2016) Tuberculosis. Lancet 387(10024):1211-1226.
683	2.	Chakaya J, et al. (2021) Global Tuberculosis Report 2020 - Reflections on the Global TB
684		burden, treatment and prevention efforts. Int J Infect Dis.
685	3.	Magro P, et al. (2020) Impact of the SARS-CoV-2 epidemic on tuberculosis treatment
686		outcome in Northern Italy. Eur Respir J 56(4).
687	4.	Migliori GB, et al. (2020) Worldwide Effects of Coronavirus Disease Pandemic on
688		Tuberculosis Services, January-April 2020. Emerg Infect Dis 26(11):2709-2712.
689	5.	Dheda K, et al. (2017) The epidemiology, pathogenesis, transmission, diagnosis, and
690		management of multidrug-resistant, extensively drug-resistant, and incurable
691		tuberculosis. Lancet Respiratory Medicine 5(4):291-360.
692	6.	(WHO) WHO (2018) Global Tuberculosis report 2018.
693	7.	Manjelievskaia J, Erck D, Piracha S, & Schrager L (2016) Drug-resistant TB: deadly,
694		costly and in need of a vaccine. Trans R Soc Trop Med Hyg 110(3):186-191.
695	8.	Desikan P (2013) Sputum smear microscopy in tuberculosis: is it still relevant? Indian J
696		Med Res 137(3):442-444.
697	9.	Olaru ID, Heyckendorf J, Grossmann S, & Lange C (2014) Time to culture positivity and
698		sputum smear microscopy during tuberculosis therapy. PLoS One 9(8):e106075.
699	10.	Su WJ, Feng JY, Chiu YC, Huang SF, & Lee YC (2011) Role of 2-month sputum smears
700		in predicting culture conversion in pulmonary tuberculosis. Eur Respir J 37(2):376-383.
701	11.	Saul EE, et al. (2020) The challenges of implementing low-dose computed tomography
702		for lung cancer screening in low- and middle-income countries. Nature Cancer
703		1(12):1140-1152.
704	12.	Miller C, Lonnroth K, Sotgiu G, & Migliori GB (2017) The long and winding road of
705		chest radiography for tuberculosis detection. Eur Respir J 49(5).
706	13.	Heo EY, et al. (2009) Radiographic improvement and its predictors in patients with
707		pulmonary tuberculosis. Int J Infect Dis 13(6):e371-376.
708	14.	Chakraborthy A, Shivananjaiah AJ, Ramaswamy S, & Chikkavenkatappa N (2018) Chest
709		X ray score (Timika score): an useful adjunct to predict treatment outcome in
710		tuberculosis. Adv Respir Med 86(5):205-210.
711	15.	Ralph AP, et al. (2010) A simple, valid, numerical score for grading chest x-ray severity
712		in adult smear-positive pulmonary tuberculosis. <i>Thorax</i> 65(10):863-869.
713	16.	Anonymous (2020) WHO consolidated guidelines on tuberculosis: Module 4: Treatment
714		- Drug-resistant tuberculosis treatment, WHO Guidelines Approved by the Guidelines
715		Review Committee, Geneva).
716	17.	Lang M, et al. (2019) mlr3: A modern object-oriented machine learning framework in R.
717		Journal of Open Source Software 4(44).
718	18.	Tverdal A (1986) Body mass index and incidence of tuberculosis. Eur J Respir Dis
719		69(5):355-362.
720	19.	Lonnroth K, Williams BG, Cegielski P, & Dye C (2010) A consistent log-linear
721		relationship between tuberculosis incidence and body mass index. Int J Epidemiol
722		39(1):149-155.

Rajagopalan S (2001) Tuberculosis and aging: a global health problem. *Clin Infect Dis* 33(7):1034-1039.

725

726 Supporting Information

727 **S1 Table.** Case characteristics of the cohort of cases selected for evaluation of baseline

728 sputum microscopy status (N = 572). Case characteristics were compared by baseline sputum

- 729 microscopy status. P-values were calculated for continuous variables (age_of_onset, bmi,
- 730 overall_timika) using analysis of variance test. P-values for categorical variables
- 731 (registration_date, gender, country, type_of_resistance, outcome, current_smoker) were
- 732 calculated using Chi-squared test.
- 733

734 S2 Table. Case characteristics of the cases with CXR radiologist observations used for

- assessing Timika Score in relation to other case characteristics (N = 1761). Cases in the TB
- portals publicly shared dataset having a CXR with available radiologist were selected. The case
- 737 characteristics are shown.
- 738

739 S3 Table. CXR derived features from radiologist observations in the cohort of cases

respected for evaluation of baseline sputum microscopy status (N = 572). The derived features

from the available radiologist observations from the cohort of selected cases used for evaluation

- of baseline sputum microscopy status were compared by baseline sputum status. P-values were
- calculated for continuous variables (mean_collapse, mean_smallcavity, mean_mediumcavity,
- mean_largecavity, mean_lowden, mean_medden, mean_highden, mean_smallnodule,
- 745 mean_mediumnodule, mean_largenodule, mean_hugenodule,
- 746 mean_lowgroundglassdensityactivefreshnodules, mean_fibroticnodule, mean_calcsequella,
- 747 overall_timika) using analysis of variance test. P-values for categorical variables (both_lungs,
- both_collapse1, both_smallcavity1, both_mediumcavity1, both_largecavity1,
- both_isanylargecavitymult, both_multiplecavitiesbeseen, both_lowden1, both_medden1,
- both_highden1, both_smallnodule1, both_mediumnodule1, both_largenodule1,
- both_hugenodule1, both_calcnod, both_noncalcnod, both_clustnod, both_multnod,
- both_lowgroundglassdensityactivefreshnodules1, both_fibroticnodule1, both_calcsequella1)
- 753 were calculated using Chi-squared test.
- 754
- 755

756 S4 Table. Patient and condition ids for the cohort of cases selected for evaluation of

- 757 **baseline sputum microscopy status (N = 572).** A table of patient and condition ids is provided
- 758 for the de-identified records that were used for evaluation of baseline sputum microscopy status.
 759

760 S5 Table. Patient, condition, and imaging ids for the cases having CXRs with radiologist

761 observations used for assessing Timika Score in relation to other case characteristics (N =

1761). A table of patient, condition, and imaging ids with associated relative date of imaging is

763 provided for the de-identified records that were used for Timika visualizations. For images used

- for temporal analysis of changes in Timika Score over time, the temporal_analysis column
- provides a filter equal to "yes" to select only those sets of images.













Timika score stratified by sputum smear status of specimen prior to treatment start from CXR within two weeks of specimen collection date



A Comparison bootstrapping without replacement (N = 200) from best models

learner_id 🧮 flact.cb.enc.zv.num_scale.pca.classif.featureless 🧮 flact.cb.enc.zv.num_scale.flt.auc.classif.multinom 🧮 timika.num_scale.cb.classif.rpart

